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Pregnancy is something that most women will go through during their lives, so it 
potentially affects half of the world’s population. The placenta mediates nutrients 
and waste products between the mother and the fetus during pregnancy. It is 
essential for a successful pregnancy outcome that the placental unit is working as 
intended, growing and adapting to fetal needs through pregnancy. The placenta 
expresses many different protein-coding genes with various purposes to function 
as required, some of which also reach the maternal bloodstream. It is still not fully 
known how the regulation of all these genes and proteins is carried out at the 
exact times it is needed. However, when the placental gene expression profiles 
have strayed from the norm, pregnancy complications can occur. 
Early pregnancy complications such as ectopic pregnancies or miscarriages 
often result in the loss of pregnancy. Even though late pregnancy complications 
have better outcomes, there is still danger to maternal and fetal life. Many of these 
have also been linked to placental dysfunction, such as preeclampsia (PE) and 
fetal growth restriction. Preeclampsia occurs in up to 5% of pregnant women 
worldwide, claiming about 63,000 maternal lives each year in the middle- and 
low-income countries, where healthcare is not always available (Burton et al., 
2019). Only palliative care is possible during the pregnancy as the removal of the 
placenta is the only known cure for PE. However, the sooner PE is diagnosed, the 
better the chances to keep the symptoms under control until birth. For this, high-
risk women need to be identified as early as possible in the pregnancy. There are 
known risk factors for PE, such as nulliparity, body mass index, and previous PE 
history, that are considered when assessing the risk for PE. Genetic risk factors 
would have an added value as these are determined only once and retain the 
information for subsequent pregnancies. Not many robust genetic risk factors 
have been determined for PE so far. 
Expression quantitative trait loci (eQTLs) are variants that modify the target 
gene expression. In the Genotype-Tissue Expression (GTEx) project (Aguet et 
al., 2020), analyzing 49 tissues revealed over 5 million variants that affect at least 
one gene in at least one tissue. Many eQTLs are also tissue-specific, making it 
necessary to study the variants in the tissue of interest. Even though eQTLs are 
well studied in readily available tissues such as blood, pregnancy-related tissues, 
such as the placenta, have only recently been started to be addressed. Identifying 
placental eQTLs could provide additional insight into placental gene expression 
regulation as well as provide a list of new candidate genes and variants for various 
pregnancy complications. 
The main aim of the current thesis was to describe the regulatory effect of 
eQTLs on placental transcriptome and the link to pregnancy complications. 
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2. LITERATURE REVIEW 
2.1. Human pregnancy 
2.1.1. Pregnancy course 
Human pregnancy lasts on average for about 40 weeks. The pregnancy is initiated 
by the fusion of an egg and a sperm in the fallopian tube. During the first two 
weeks, the resulting embryo moves from the tube into the uterus, where the 
embryonic trophoblast cells begin to invade into the maternal decidua (James 
et al., 2012). These invading trophoblasts create the basis for the placenta. 
The pregnancy is divided into three trimesters, each focusing on different fetal 
development and growth stages. As the embryo develops, the conditions needed 
for optimal growth change. In the first trimester (up to 11th gestational week), the 
embryo is growing in a hypoxic environment until the remodeling of decidual 
spiral arteries occurs (Jauniaux et al., 2000; Rodesch et al., 1992). Until then, the 
primary source of nutrition for the embryo comes from the secretions of the endo-
metrial glands (Burton et al., 2002). Therefore, during this period, maternal circu-
latory factors do not reach the embryo in large quantities. However, the substances 
secreted by the placenta and the embryo still reach the maternal bloodstream even 
at this time. (Huppertz et al., 2008; Michelsen et al., 2019) All fetal structures and 
major organs start their development already during the first trimester.  
At the start of the second trimester, the placenta has developed into a fully 
functional organ, and maternal blood is used as the primary source of nutrition 
for the fetus (Aplin et al., 2020; Jauniaux et al., 2000). Other fetal organs continue 
their development in the second and third trimesters. In the third trimester, the 
fetus goes through rapid growth, gaining weight. In addition, the nervous system, 
lungs, and metabolism mature to adjust to life out of the uterus. 
 
 
2.1.2. Placenta, a pregnancy-specific organ  
at the maternal-fetal interface 
The placenta is a unique organ (Table 1). It is the only organ present only at a 
specific time point in human life – pregnancy. It is constantly changing to meet 
the needs of the growing embryo, reaching full-thickness by the fourth gestational 
month but continuing to grow in circumference through pregnancy. The central 
role of the placenta is to mediate maternal and fetal needs. Nutrients and oxygen 
are moved through the placenta, from the mother to the fetus, with waste pro-
ducts, and secreted proteins moved in the opposite direction (Aplin et al., 2020; 






Table 1. Examples of some notable features of the human placenta  
Features Reference 
Evolutionarily new endocrine organ, present only in 
mammals 
(Burton & Fowden, 2015; 
Cross et al., 2003) 
It is a temporary organ (Burton & Fowden, 2015; 
Fox & Sebire, 2007) 
Contains new cell types  
a) syncytiotrophoblast that is the only true multinuclear 
syncytium 
b) extravillous trophoblasts that are capable of invading 
maternal decidua deeper than other mammals
(Burton & Fowden, 2015; 
Cross et al., 2003; Fox & 
Sebire, 2007) 
Organ function-specific genes, proteins, and miRNA 
families 
(Liang et al., 2007; Rawn 
& Cross, 2008) 
General hypomethylation of the genome compared to 
postnatal somatic and fetal cells
(Ehrlich et al., 1982; 
Schroeder et al., 2013) 
The placental genome is prone to changes, including 
somatic mutations, genomic chromosomal instability 
with confined placental mosaicism
(Coorens et al., 2021; 
Kalousek & Dill, 1983; 
Kasak et al., 2015, 2017) 
The placental microbiome is nearly absent (de Goffau et al., 2019; 
Leiby et al., 2018) 
 
The primary cell type in the placenta that makes it functional is trophoblasts. 
During the invasion phase, cytotrophoblast (CTB) differentiates into two dif-
ferent types: multinuclear syncytiotrophoblast (STB) and mononuclear, highly 
invasive extravillous trophoblast (EVT). By the third gestational week, the 
placenta has vascularized villi bathed in the maternal blood in the intervillous 
space (Figure 1.) (Demir et al., 1989; Te Velde et al., 1997). Placental villi consist 
of layers of CTB and STB cells covering the fetal blood vessels (Fox & Sebire, 
2007). Remodeling of the spiral arteries widens and relaxes them locally, so in-
creased blood flow into the placenta is possible. Incomplete remodeling is thought 
to be one of the underlying causes of maternal hypertension, preeclampsia (PE), 
and fetal growth restriction (Staff, 2019). 
The human placenta is hemochorial, which means the chorionic villi come 
into direct contact with maternal blood. Even among the same type of placentas 
among mammals, the human placenta has a profound trophoblast invasion, even 
up into a third of the maternal myometrium. A similar pattern has also been found 
in gorillas and chimpanzees, but not in Old World monkeys (Carter, 2011). The 
most commonly used model animal, the mouse, has reasonably different morpho-
logy from a human placenta despite being hemochorial (Figure 2.) (Hemberger 
et al., 2020). The absence of a perfect model is one of the reasons researching the 




Figure 1. Structure of the human placental-maternal interface. Adapted from (A. R. Clark 
et al., 2020). AV, arteriovenous 
 
 
Figure 2. Comparison between the mouse and the human placenta. Adapted from (Hem-
berger et al., 2020). E, embryonic day; STB, syncytiotrophoblast; SpT, spongiotrophoblast; 





 Mouse Human 
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The placenta releases different hormones, microRNAs (small single-stranded 
RNAs), cell-free DNA, extracellular vesicles, and other products into the maternal 
blood stream at specific time points during pregnancy. Different estrogens and 
progesterone are produced by the placenta, as well as some placenta-specific 
peptide hormones like human chorionic gonadotropin (hCG) (Bonduelle et al., 
1988; Rull et al., 2008), human placental lactogen (hPL) (Kliman et al., 1986; 
Männik et al., 2010), human placental growth hormone (PGH) (Alsat et al., 1997), 
and others (Costa, 2016; Fox & Sebire, 2007). According to Human Protein Atlas 
(proteinatlas.org, (Uhlen et al., 2015)), there are 91 genes with expression 
enriched for the placenta (>4 times higher mRNA levels than in any other tissue). 
Among these are some well-known genes like pregnancy-specific glycoprotein 
family (PSG1-9), pappalysin 1 and 2 (PAPPA1-2), fms-like tyrosine kinase 1 
(FLT1), placental alkaline phosphatase (ALPP), insulin-like growth factor 2 
(IGF2), and others. Predominantly placenta-expressed genes are expressed 
mainly by trophoblast cells and are integral to trophoblast differentiation and 
function (Handwerger & Aronow, 2003; Szilagyi et al., 2020). The placental 
products can affect the maternal physiology and response to pregnancy and, there-
fore, potentially the pregnancy outcome. For example, placenta-derived soluble 
Flt-1 (sFlt-1) rises in the maternal serum about five weeks before developing PE 
(D. E. Clark et al., 1998; Levine et al., 2004).  
 
 
2.2. Pregnancy complications 
2.2.1. General overview 
Pregnancy affects the whole maternal body causing anatomic, hormonal, and 
metabolic changes in several organs. When the maternal body is not able to adapt 
to the changes, complications can occur. Many obstetrical complications have 
been linked to the placenta, either by insufficient or excessive invasion (Brosens 
et al., 2011; Burton & Jauniaux, 2018; Jauniaux et al., 2018). Depending on the 
timing, these can be broadly divided into two groups – early and late pregnancy 
complications.  
Early pregnancy complications such as ectopic pregnancy, miscarriage, and 
molar pregnancy are severe and incompatible with pregnancy continuation. If not 
removed, ectopic and molar pregnancies can become life-threatening for the 
mother (Rehman & Muzio, 2019). A brief overview of selected early pregnancy 
complications can be found in Table 2. 
Even though late pregnancy complications manifest in the second half of the 
pregnancy, the cause can be already present in early pregnancy. For example, PE 
and fetal growth restriction are thought to be mainly caused by inadequate placental 
invasion (Burton & Jauniaux, 2018; Staff, 2019). In general, late pregnancy 
complications are less severe but can become life-threatening to the child and the 






















































































































































































































































































































































































































































































































































































































































































































































































































































2.2.2. Preeclampsia – a placental disease in late pregnancy 
Preeclampsia (PE) is a syndromic pregnancy complication characterized by de 
novo onset of hypertension accompanied by other maternal organ damage symp-
toms. No one symptom is specific for PE, but the collection of symptoms is used 
for the diagnosis. Current diagnostic criteria endorsed by the International Society 
for the Study of Hypertension in Pregnancy (ISSHP) are as follows: 
Gestational hypertension (systolic BP ≥140 and/or diastolic BP ≥90 mmHg) 
with one or more new-onset conditions ≥20th gestational week: 
 
a) Proteinuria 
b) Other maternal organ dysfunction (acute kidney injury, elevated trans-
aminases indicating liver damage, neurological complications, hematological 
complications) 
c) Uteroplacental dysfunction (fetal growth restriction, abnormal Doppler 
analysis, stillbirth) (Brown et al., 2018) 
 
Preeclampsia affects about 4.6% of pregnant women globally, but regional 
differences can be vast (Abalos et al., 2013). In Estonia, the incidence of PE in 
2019 was about 1.7%, according to Estonian Health Statistics and Health Research 
Database (www.statistika.tai.ee/). Advances in health care have reduced PE-
related mortality among mothers in high-income countries (0.03% in the UK) but 
remains an issue in the middle- and low-income countries accounting for 63 000 
maternal deaths per year (Burton et al., 2019). 
Currently, the clinical focus is finding the high-risk women, surveillance and 
managing the emerging symptoms, and delaying preterm delivery unless mater-
nal health is at risk. Some at-risk women benefit from low-dose aspirin treatment 
started at 16–20th week of gestation to reduce the incidence of PE or the severity 
of the symptoms (Brown et al., 2018). When the low-dose aspirin treatment was 
started at 11–14th week for high-risk women, the reduction of preterm PE was 
over 60% (Rolnik et al., 2017). The end of pregnancy and departure of the placenta 
is currently the only definitive cure for PE. 
Within PE, two distinct subtypes are differentiated according to the time of 
presentation of symptoms (Lisonkova & Joseph, 2013). The common consensus 
is that early-onset PE (EOPE) manifests from 20th to 34th gestational week and late-
onset (LOPE) from 34th week onward (Tranquilli et al., 2013). EOPE tends to 
have more severe symptoms and results more often in preterm delivery. The two 
subtypes of PE are also thought to have differing pathologies. Whereas insufficient 
placental invasion is the leading cause of early PE, late-onset PE is believed to be 






Figure 3. Pathways to the development of preeclampsia (PE). Adapted from (Aplin et al., 








2.2.3. Diagnostic and prognostic biomarkers of pregnancy 
complications 
In Estonia, screening for fetal chromosomal and gross anatomical abnormalities 
is carried out during the first trimester visits from the 11th to 14th gestational week. 
The risk for early PE can also be assessed during the first trimester by utilizing 
serum PAPP-A, placental growth factor (PlGF), and uterine artery Doppler 
combined with maternal characteristics and medical history in an algorithm by 
the Fetal Medicine Foundation (FMF) (O’Gorman et al., 2016; Tan et al., 2018). 
The FMF algorithm has been in use in Estonia since 2019. 
Some less established biomarker screenings for late pregnancy have been 
proposed for a few pregnancy complications (Table 3). National Institute for 
Health and Care Excellence (NICE) guidance recommends additional use of 
commercial PlGF/sFlt-1 ratio or the Triage PlGF test for excluding the mani-
festation of both early and late PE up to four weeks in the second or third trimester 
(Herraiz et al., 2018; NICE, 2016). Fetal fibronectin can be used to assess 
immediate risk for preterm birth in the next 48 hours (NICE, 2015).  
The clinical risk factors for gestational diabetes (GD) include high fasting 
blood sugar, glycosuria, excessive weight gain, pre-pregnancy body mass index 
(BMI) ≥25 kg/m², prior GD, familial diabetes, previous newborn >4500g, and 
polycystic ovary syndrome are associated with GD. The presence of any of these 
demand a glucose tolerance test (GTT) at 24–28 gestational weeks to detect 
abnormal carbohydrate metabolism and GD (Hod et al., 2015). Blood pressure 
measurement and urine test at every visit after 20th gestational weeks are used to 
discover gestational hypertension or PE. Small- (SGA) and large-for-gestational-
age (LGA) newborns are diagnosed most commonly after birth according to sex-
adjusted growth curves. Still, they can be predicted during pregnancy by esti-
mating the fetal weight by fundal height measurements and/or during the ultra-
sound scan (Sildver et al., 2015) (Table 3). 
 
 
2.3. Genetics of late pregnancy complications 
2.3.1. Challenges in the genetic research  
of pregnancy complications 
Researching pregnancy complications offers some unique challenges. To start, in 
most diseases, the influence of the individual’s genetic makeup together with 
environmental factors is studied. In pregnancy, there is a third counterpart – the 
fetal genome. This also complicates the choice of study subjects; either the mother, 




Most pregnancy complications have been acknowledged to be multifactorial, 
affected by maternal and fetal genetics and lifestyle. However, the exact pro-
portions have not been identified for all complications at this time. For PE, it has 
been estimated that maternal genetic factors account for 35–38% and placental 
20–21% to a combined heritability of 55–59% (Cnattingius et al., 2004; Steint-
horsdottir et al., 2020). The heritability of SGA and LGA is not established. 
However, combined genetic contributions have been proposed to account for up 
to 50% of the birth weight variation (Clausson et al., 2000).  
An additional challenge is the approach of analysis. One option is to inves-
tigate candidate genes where a hypothesis of effect can be easily constructed from 
previous knowledge. However, the selection is limited by the current under-
standing of the disease pathophysiology. Genes may be selected based on sig-
naling or biochemical pathways. The main drawback of this approach is that not 
all contributors to the disease pathophysiology might be known already. Previ-
ously, candidate gene based studies have had low reproducibility, possibly due to 
small sample sizes. Another method can be used to overcome this aspect – 
genome-wide association studies (GWAS). GWAS offers a hypothesis-free 
analysis of the whole genome, enabling the identification of novel candidate 
genes. However, a significant drawback of this method is the need for extensive 
sample sets to detect significant associations after correcting for multiple testing. 
Collecting large sample sets of pregnancy-related tissues such as placental samples 
has been more complex than simple blood samples.  
 
 
2.3.2. Genetics of preeclampsia 
As the disease, so is the genetics of PE complex. Hundreds of genes and variants 
have been associated with PE. However, only a small portion of the finds have 
been replicated in separate studies. The genetic background of PE might partly 
be shared with other traits such as elevated diastolic blood pressure (DBP) and 
high BMI (Gray et al., 2021). However, genetic risk scores for hypertension or 
DBP were not found to be predisposing PE, indicating still different underlying 
pathways (Smith et al., 2016). 
Another complicating factor of PE genetics is the sub-types of PE. There is a 
consensus that EOPE and LOPE have different genetic backgrounds (Burton et al., 
2019; Oudejans et al., 2007), but a few studies have proposed other genetically 
distinct PE subsets (Leavey et al., 2015, 2016). Using aggregate data from several 
gene expression microarray-based studies, Leavey et al., 2016 proposed three 
distinct PE subgroups – canonical”, immunological”, and maternal” PE. How-
ever, the gene expression profiles of immunological” and maternal” PE patients 
were not as distinct from controls as canonical” PE patients. This also illustrates 
the importance of group selection for conducting studies on PE, especially with 
smaller sample sizes. The collection of a more distinct PE group might reduce the 
noise and improve the results. 
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2.3.2.1. Candidate gene studies for preeclampsia 
Traditionally, PE candidate genes have been selected from various affected 
pathways, including endothelial function (e.g., renin-angiotensin system, FLT1), 
the oxidative stress and thrombophilia pathways, hemodynamics, immune response 
(e.g., IL-10, TNF-a, HLA-G), and lipid metabolism (Thakoordeen et al., 2018; 
Williams & Broughton Pipkin, 2011). However, many of the candidate gene 
studies have conflicting results. 
Most studies so far have been conducted on maternal samples. These are more 
readily available as maternal blood samples are taken routinely during pregnancy. 
Another reason to prefer maternal samples is that they are less invasive than 
placental or fetal samples that can be taken during pregnancy. Therefore, maternal 
samples have a higher potential for later clinical use. 
A study using maternal samples focusing on approximately 2000 cardio-
vascular candidate genes (including 27 429 variants) was recently conducted 
(Gray et al., 2018). Only one variant (rs9478812) in the PLEKHG1 gene reached 
statistical significance in the multiethnic meta-analysis (OR=1.40, 95% CI 1.23–
1.60, P=5.9×10–7). The gene is expressed in most tissues and has been previously 
associated with blood pressure, body weight, and neurological disorders, but the 
exact function of PLEKHG1 is still largely unknown. 
Placental stanniocalcin-1 (STC1), a glycoprotein hormone that regulates 
calcium homeostasis in fish (Wagner et al., 1986), is a relatively new candidate 
gene for PE. It has been shown to exhibit trimester-specific dynamics and higher 
levels in term PE placentas. Maternal serum levels of STC1 have also been shown 
to have increased in post-PE pregnancy samples (Uusküla et al., 2012). The 
hormone expression increases in hypoxic conditions in the BeWo cell line, 
possibly to protect the placenta against low oxygen in PE (Abid et al., 2020). STC1 
expression has been shown to increase in the endometrium in the mid-secretory 
phase and is dysregulated in endometriosis and polycystic ovary syndrome 
(Aghajanova et al., 2016; Khatun et al., 2020).In animal models, several re-
productive phenotypes have been linked to STC1, such as ovarian function (Deol 
et al., 2000), implantation (Song et al., 2009), gestation, and lactation (Deol et al., 
2000; Varghese et al., 2002). STC1 seems to have a diverse functionality in 
mammals, and the evidence for importance in pregnancy is increasing. 
FLT1, on the other hand, is one of the best-known candidate genes for PE. As 
the sFlt-1 inhibits angiogenesis in the placental vasculature through trapping 
VEGF-A, it is a clear candidate for PE pathophysiology (Shibuya, 2013). The 
soluble form of Flt-1 is not expressed in many other tissues besides the placenta, 
but for example, the avascularity of the cornea is maintained by sFlt-1 (Ambati 
et al., 2006). Placenta-derived sFlt-1 is known to increase in maternal serum 
slightly before and during a presentation of PE symptoms (Levine et al., 2004; 
Maynard et al., 2003). The gene expression levels in the placenta have also been 
shown to rise in PE (Uusküla et al., 2012). The genetics behind FLT1 isoform 
splicing are still poorly known. One region in FLT1 intron 13 has been shown to 
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regulate the alternative splicing of the gene but only had a modest effect on sFlt-
1 isoform abundance (Thomas et al., 2010). 
 
2.3.2.2. Linkage studies for preeclampsia 
The first genome-wide scan for susceptibility loci in PE was conducted using 
linkage analysis of 15 Australian families (Harrison et al., 1997). The study iden-
tified a region on chromosome 4q that was associated with PE. Four more linkage 
studies have been conducted on family sets from Iceland (Arngrímsson et al., 
1999), Australia/New Zealand (Moses et al., 2000), Netherlands (Lachmeijer et 
al., 2001), and Finland (Laivuori et al., 2003). Arngrimsson et al. and Moses et 
al. identified both a region on chromosome 2 associated with PE. Moses et al. and 
Laivuori also detected nominal significance for the 4q region identified by 
Harrison et al. However, other regions among these studies did not replicate. 
 
2.3.2.3. Genome-wide studies for preeclampsia 
A handful of GWA studies have been conducted for PE in maternal samples 
(Table 4); however, very few variants have reached significance, and none have 
been replicated in independent datasets (Burton et al., 2019). A HAPO study (137 
cases, 2986 controls) (Zhao et al., 2013), as well as an earlier study (177/116) 
(Zhao et al., 2012), did not identify any significant single nucleotide variants 
(SNVs) after correction for multiple testing. Another GWAS (538/540) identified 
a single independent signal near the INHBB gene (Johnson et al., 2012). Most 
recent maternal GWAS applying 12,150 PE cases and 164,098 controls impli-
cated two variants near ZNF831 and FTO genes. Both variants have been previ-
ously implicated with blood pressure levels, and the FTO variant also with several 
other metabolic traits (Steinthorsdottir et al., 2020). 
As genome-wide studies in maternal samples have not brought expected 
success, more studies have been conducted in placental samples (Table 4). 
Recently, the first PE GWAS was conducted in placental tissue (4,380/310,238), 
identifying only one variant (rs4769613) near the FLT1 gene with genome-wide 
significance despite the large sample size (McGinnis et al., 2017). Another recent 
GWAS included Central Asian placentas in addition to European samples and 
confirmed the previously detected association between late-onset PE and FLT1 
variant rs4769613 (linkage disequilibrium (LD) SNP rs4769612 was used in the 
study) (Steinthorsdottir et al., 2020). FLT1 is a known PE candidate gene as the 
soluble form of the encoded protein rises sharply in maternal serum in response 



















Without using extensive datasets, it is clear that it is difficult to identify any clear 
associations with PE as the syndrome is so varied. However, large datasets for 
placental tissues are not common, so defining a distinct subgroup could help 
analyze candidate genes also in smaller sample sets 
 
 
2.4. Direct effect of genetic variation  
on gene expression levels 
2.4.1. Expression quantitative trait loci – eQTLs 
Single nucleotide variants in the genome that affect the expression of specific 
genes are historically called expression quantitative trait loci (eQTLs, Farrall, 
2004) and just eSNVs or eVariants. The first study to assess the genetic variants 
affecting gene expression genome-wide was done in yeast only 20 years ago 
(Brem et al., 2002) and in mammals a year later (Schadt et al., 2003). The largest 
project to map such variants to date in humans is The Genotype-Tissue Expres-
sion (GTEx) Project. The GTEx project has mapped over 4 million eQTLs 
affecting gene expression in at least one of the 49 tested tissues (Aguet et al., 
2020). These variants have been shown to modulate the expression of 94.7% of 
all protein-coding genes. 
eQTLs can be divided into two subtypes based on their distance from the 
affected gene (Figure 4). Nearby variants (cis-eQTLs) are located up to 1Mb 
from the gene; however, the definition can vary among different studies. Trans-
eQTLs, on the other hand, can be located even on another chromosome, the effect 
on gene regulation mediated by three-dimensional links or intermediate genes. 
Most cis-eQTLs tend to be less tissue-specific than trans-eQTLs; among both, the 
specificity follows a U-curve with a higher percentage of both tissue-specific and 
highly universal variants (Aguet et al., 2020).  
Other, more specific types of eQTLs have also been proposed. Dynamic eQTLs 
exhibit temporal influence on gene expression, only regulating the mRNA levels 
in specific time periods. During differentiation from induced pluripotent stem cell 
(iPSC) to cardiomyocytes, a linear dynamic eQTL effect was found for 550 genes 
(Strober et al., 2019). Additionally, 693 genes were suggested to exhibit nonlinear 
eQTL effects, with 28 having the highest effect in the middle. Similarly, during 
iPSC differentiation to endoderm, about 30% of identified eQTLs were stage-
specific (Cuomo et al., 2020). However, dynamic eQTL analysis has been limited 
primarily to in vitro studies due to the inaccessibility of in vivo tissue samples. 
Such dynamic cis-eQTLs in early development might appear to act in trans later 
in life (Umans et al., 2020). Another subtype of dynamic eQTLs is a response or 
conditional eQTLs that only have an effect in certain conditions, usually to a 
response to an extrinsic stimulus. Change in the set of identifiable eQTLs has 
been shown in monocytes after stimulation, imitating innate immune response 
(Fairfax et al., 2014). 
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Variants having an allele-specific effect on gene expression variance instead 
of the mean value have been proposed (dispersion QTLs, dQTLs), possibly 
affecting disease penetrance (Sarkar et al., 2019). However, the detection of such 
variants needs massive datasets due to the considerable influence of non-genetic 
background. 
 
Figure 4. Both cis- and trans-eQTLs can affect gene expression.  
 
 
2.4.2. eQTLs and human disease 
The first eQTL screen done in a mouse also identified that some eQTL loci are 
linked to murine obesity subtypes (Schadt et al., 2003). The authors also proposed 
that combining gene expression, genotype, and clinical data could help identify 
underlying pathways. Since then, combining GWAS and eQTL data from appro-
priate tissue has become a common practice (Cookson et al., 2009, Table 5). As 
most variants identified in GWAS are intragenic, it can be challenging to deter-
mine the functional relevance to the disease (Maurano et al., 2012). As more and 
more eQTL studies are conducted in various tissues, these results are integrated 
with GWAS data. Without additional information on the variants, usually closest 
genes to the GWAS variant were prioritized. However, a study demonstrated that 
among 104 identified functionally relevant genes after eQTL data integration for 
five GWAS traits, even as much as two-thirds were not the nearest gene (Z. Zhu 
et al., 2016).  
Several studies have demonstrated enrichment of eQTLs among variants 
identified in GWAS, both in the whole catalog and in specific diseases or traits 
(Table 5)(Aguet et al., 2020; Peng et al., 2017; Viñuela et al., 2020). Overall, the 
GTEx project identified cis-eQTLs have a 1.46-fold enrichment among GWAS 
catalog variants. Some studies have also used eQTL data to prioritize candidate 
genes from GWAS data to further investigate diseases such as osteoarthritis and 
Crohn’s disease (Marigorta et al., 2017; Tachmazidou et al., 2019). Whether the 
co-localization is due to pleiotropic effects or mediated by gene expression changes 
is unclear in many cases. Defining the cause is made more challenging by diffi-










































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.5. Summary of the literature review 
The placenta is a unique, transient organ in human pregnancy delivering oxygen 
and nutrients to the fetus. In addition, the placenta acts as an endocrine organ, 
synthesizing macromolecules that modify the course of gestation. It has been 
shown that in several pregnancy complications, such as fetal growth restriction 
and PE, the placental transcriptome profile is significantly changed. PE is a serious 
complication that affects up to 5% of pregnant women, posing a risk for maternal 
and fetal health. Many candidate genes have been identified for PE, but few have 
been replicated in independent sample sets. FLT1 is a well-known PE candidate 
gene that codes sFlt-1, a soluble molecule that reaches maternal serum rising few 
weeks before PE symptoms. Even for FLT1, the exact genetic causes behind the 
gene expression changes are not well known. 
Genetic variation associated with specific gene expression changes is one of 
the proposed processes behind the precise placental expressional dynamics. Such 
variants, commonly called expression quantitative trait loci or eQTLs, have been 
identified in many tissues. Many of the variants are tissue-specific and the data 
cannot be transferred to other tissues. Previously, it has been noted that many 
eQTLs co-localize with GWAS loci, suggesting their role in risk for disease 
development. Identifying placental eQTLs could provide further insight into 
pregnancy gene expression dynamics as well as pregnancy complications. How-
ever, only a few studies have conducted placental eQTL analyses so far. 
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3. AIMS OF THE PRESENT STUDY 
The general aim of this thesis was to explore and describe the landscape of 
placental genetic regulation of gene expression through expression quantitative 
trait loci (eQTLs) and their role in the development of pregnancy complications.  
 
The specific aims of this thesis were: 
 
1. To investigate eQTLs of candidate genes for preeclampsia, STC1 and FLT1. 
 
2. To identify and characterize robust placental eQTLs in the placental tissue. 
 
3. To compile the current knowledge of placental eQTLs identified for candidate 
genes and in transcriptome-wide association studies. 
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4. MATERIAL AND METHODS 
4.1. Ethics 
The protocols of REPROMETA (full study name: REPROgrammed fetal and/or 
maternal METAbolism) and HAPPY PREGNANCY (full study name: Develop-
ment of novel non-invasive biomarkers for fertility and healthy pregnancy) 
studies were reviewed and accepted by the Ethics Review Committee of Human 
Research of the University of Tartu, Estonia (permissions no 146/18, 27.02.2006; 
150/33, 18.06.2006; 158/80, 26.03.2007; 221/T-6, 17.12.2012; 286/M-18, 
15.10.2018).  
Ethical approval for the Avon Longitudinal Study of Parents and Children 
(ALSPAC) was obtained from the ALSPAC Ethics and Law Committee and the 
Local Research Ethics Committees. Consent for biological samples was collected 
in accordance with the Human Tissue Act (2004). Informed consent for the use 
of data collected via questionnaires and clinics was obtained from participants 
following the recommendations of the ALSPAC Ethics and Law Committee. 
The Finnish Genetics of Preeclampsia Consortium (FINNPEC) study protocol 
was approved by the coordinating Ethics Committee of the Hospital District of 
Helsinki and Uusimaa. The Southern Finnish participant study was approved by 
the local ethical review committee at the Helsinki University Hospital. 
All subjects provided written informed consent. All procedures and methods 




4.2. Study subjects 
4.2.1. Recruitment and characteristics of REPROMETA and  
HAPPY PREGNANCY sample sets 
Participants of both REPROMETA (supported by HHMI#55005617 and ETF9030 
grants) and HAPPY PREGNANCY (supported by SLOMR12214T grant) studies 
were recruited at the Women’s Clinic of Tartu University Hospital, Estonia 
(2006–2011 and 2013–2015, respectively). All participants were of Caucasian 
ancestry. 
The REPROMETA study (n=377) focused on recruitment of extreme cases of 
selected pregnancy complications (preeclampsia (PE, n=53), gestational diabetes 
(GD, n=50), small- (SGA, n=72) and large-for-gestational-age newborns (LGA, 
n=97)) and uncomplicated pregnancies (NORM, n=105). The family trios or duos 
were recruited before or shortly after delivery at the Women’s Clinic. Epidemio-
logical data, reproductive history, and parental lifestyle were obtained from self-
reported questionnaires filled shortly after recruitment by both parents. Pregnancy 
outcome data was acquired from the medical records. Placental samples were 
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available for 366 cases. REPROMETA infant growth data was collected from 
questionnaires filled by the parent or the general practitioner at 6 (n=233) and 
12 months (n=216). 
Individuals in the HAPPY PREGNANCY cohort study (n=2334) were 
recruited prospectively during their first antenatal visit at the Women’s Clinic. 
The patients were asked to fill three questionnaires throughout their pregnancy 
concerning epidemiological data, reproductive history, parental lifestyle, and 
additional pregnancy course and outcome data collected from the medical records. 
Placental samples were available for 1768 singleton cases. 
HAPPY PREGNANCY consisted of PE (n=44), SGA (n=129), LGA (n=141), 
GD (n=102), preterm (n=58), and NORM (n=1294) pregnancies. 
The exact number of individuals utilized from each sample set has been noted 
in each study (Juhanson et al., 2016; Kikas et al., 2019, 2020) (Table 6). Some 
individuals were excluded from the studies due to lack of DNA or other targeted 
materials or genotyping failure. 
 
Table 6. Sample sets used in the studies 
Sample set Ref. 1 
Juhanson et al., 
2016 
Ref. 2 
Kikas et al.,  
2020 
Ref. 3 
Kikas et al., 
2019 
Estonian cohorts  
REPROMETA (REPROgrammed fetal and/or maternal METAbolism) 
Maternal DNA  50 PE/316 NPE 40 PE/253 NPE n.a. 
Maternal plasma  50 PE/316 NPE n.a. n.a. 
Paternal DNA n.a. 42 PE/227 NPE n.a. 
Placental DNA  50 PE/316 NPE 52 PE/227 NPE 336 
Placental RNA-seq n.a. n.a. 40 
Placental genotyping n.a. n.a. 40 
HAPPY PREGNANCY  
(Development of novel non-invasive biomarkers for fertility and healthy pregnancy) 
Placental DNA n.a. 44 PE/1724 NPE 408 
Maternal serum n.a. 18 PE/135 NPE n.a. 
Collaboratory cohorts  
FINNPEC (Finnish Genetics of Preeclampsia Consortium)
Maternal DNA 547 PE/513 NPE n.a. n.a. 
Umbilical cord DNA 378 PE/496 NPE n.a. n.a. 
ALSPAC (Avon Longitudinal Study of Parents and Children) 
Placental DNA n.a. n.a. 7669 




4.2.1.1. Clinical subgrouping in REPROMETA and  
HAPPY PREGNANCY sample sets 
Cases with known fetal anomalies, chromosomal abnormalities, inherited diseases, 
and pre-existing diabetes mellitus, chronic hypertension, or chronic renal disease 
were excluded from the studies. 
NORM group was defined as pregnancies uncomplicated by previously men-
tioned conditions with a newborn between 10th and 90th percentile on the growth 
curves calculated based on data from Estonian Medical Birth Registry growth 
standards (Sildver et al., 2015). SGA and LGA pregnancies had a newborn either 
<10th or over 90th percentile, respectively, on the growth curves. PE cases were 
defined as hypertensive (systolic blood pressure ≥160mmHg and/or diastolic 
blood pressure ≥110mmHg) and had proteinuria of ≥5g in 24 hours or neuro-
logical symptoms (Brown et al., 2018). PE was further subdivided into early-
onset (symptoms before 34th gestational weeks) and late-onset PE (after 34th 
gestational weeks). GD was diagnosed when 75g oral glucose tolerance test 
(GTT) performed at 24–28 weeks of gestation indicated either a fasting venous 
plasma glucose level of ≥5.1 mmol/l and/or at 1h and 2h later plasma glucose 
level of ≥10.0 mmol/l and ≥8.5 mmol/l glucose, respectively (International 
Association of Diabetes and Pregnancy Study Groups Consensus Panel, 2010). 
Pregnancies with birth before the 37th gestational week were considered preterm. 
 
 
4.2.2. Collaborative replication sample sets – ALSPAC, FINNPEC 
The Finnish Genetics of Preeclampsia Consortium (FINNPEC) study recruited 
preeclamptic and control participants in 5 university centers in Finland (Helsinki, 
Turku, Tampere, Kuopio, and Oulu) in 2008–2011 (Jääskeläinen et al., 2016). 
The controls were recruited for each PE patient by inviting the next available 
patient to give birth at the same hospital with no PE. Only individuals meeting the 
REPROMETA diagnostic criteria for PE and NORM groups were included in the 
analyses. PE patients were further divided into EO-PE (n=165) and LO-PE (n=382) 
subgroups. 
In total, 547 PE patients and 513 controls were included in the study. For fetal 
samples (n=EO-PE, n=88; LO-PE, n=290; NORM, n=496), the DNA was extracted 
from cord blood. 
The Avon Longitudinal Study of Parents and Children (ALSPAC) initially 
recruited 14,541 pregnant women residents in Avon, United Kingdom, with 
expected delivery dates from April 1, 1991, to December 31, 1992 (Boyd et al., 
2013; Fraser et al., 2013) (http://www.alspac.bris.ac.uk). For all recruited cases, 
medical data from obstetric and perinatal records were documented. From the 
initial pregnancies, 14,062 resulted in live births. Gestational age at the delivery 
was recorded the nearest gestational week. The study analyzed 7,669 newborns 
with available genotype data. Please note that the ALSPAC study website 
contains details of all the available data through a fully searchable data dictionary 
and variable search tool: http://www.bristol.ac.uk/alspac/researchers/our-data/. 
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4.2.3. Placental and blood sampling in REPROMETA and  
HAPPY PREGNANCY studies 
Placental sampling in REPROMETA and HAPPY PREGNANCY studies was 
conducted within one hour after cesarean section or vaginal delivery by trained 
nurses following the same protocol. In the meanwhile, placentas were kept at 
+4 °C. A full-thickness block of 2 cm was taken from the middle region of each 
placenta, avoiding the umbilical cord insertion site, large vessels, and any visible 
or palpable infarction, hematoma, or damage. In the HAPPY PREGNANCY 
study, this step was repeated for each quadrant of the placenta. Placental samples 
were washed with 1x PBS to remove maternal blood and subsequently divided 
into sections for DNA and RNA extraction. Tissue for RNA extraction (1 g or 
100 mg in REPROMETA or HAPPY PREGNANCY study, respectively) was 
placed into 10 ml or 1 ml RNAlater (AM7021; Thermo Fisher Scientific). Samples 
were kept in RNAlater for 1–3 days at +4 °C and then stored at –80 °C until RNA 
extraction. The rest of the tissue sample was placed into a dry tube and stored at 
–80°C until DNA extraction. 
Maternal blood sampling in the REPROMETA study was conducted on the 
day of the delivery. The blood sample was aliquoted and stored at –80 °C 
immediately after collection. Maternal plasma was extracted from the same sample 
during aliquoting. 
Maternal serum samples from HAPPY PREGNANCY individuals were col-
lected during routine blood tests throughout pregnancy and stored at –80 °C. 
 
 
4.3. Utilized resource: placental whole-genome datasets 
4.3.1. Placental RNA-Seq dataset 
The REPROMETA placental RNA sequencing dataset was first published by 
Sõber et al., 2015. The dataset included 40 term placentas from various pregnancy 
outcomes (PE, SGA, LGA, GD, NORM, n=8 each). 
RNA from the placental sample (200–300mg) was extracted using the Trizol 
protocol and purified with RNeasy MinElute columns (74204; Qiagen, German-
town, MD, USA) according to the manufacturer’s protocol. NanoDrop ND-1000 
UV-Vis spectrophotometer (Applied Biosystems, Foster City, USA) was used to 
determine the purity and concentration of isolated total RNA. RIN (RNA integrity 
number) was estimated by Agilent 2100 Bioanalyzer (Agilent Technologies, USA). 
Total RNA with high purity was used for rRNA depletion (Ribo-Zero rRNA 
Removal Kit, MRZH11124; Illumina, San Diego, CA, USA) and library prepa-
ration with Nextera Technology (FC-121-1030; Illumina). Total RNA sequencing 
was conducted in Finland Institute for Molecular Medicine (FIMM) Sequencing 
Core Laboratory on Illumina Hiseq2000 using 46 bp paired-end reads. Initial data 
refinement was performed with RNA-Seq pipeline v.2.4 (FIMM; Helsinki, 
Finland). Human genome assembly (GRCh37.p7/hg19) from Ensembl v67 was 
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used as a reference. The initial dataset included gene expression data for 53,893 
genes. Gene expression was quantified by HTSeq analysis (as raw read counts) 
and later normalized for read depth using DESeq package for R. Only non-
mitochondrial genes with sufficient expression levels (>100 normalized read 
count) were considered in the analysis (n=11,733). 
 
 
4.3.2. Placental whole-genome genotyping dataset 
The same 40 samples with available RNA sequencing data also underwent whole-
genome genotyping (Kasak et al., 2015). The DNA of the placental samples was 
extracted using a NucleoSpin Tissue kit (Macherey-Nagel, Germany) according 
to the manufacturer’s instruction. The genotyping was conducted with Illumina 
HumanOmniExpress-12-v1 BeadChip at the institutional genotyping core facility 
(Estonian Genome Center; http://www.geenivaramu.ee/en). The array included 
>733,000 SNPs with a median spacing of 2.1 kb. Samples were genotyped with 
an average overall call rate >99% per individual per genotype. 
Variants deviating from Hardy-Weinberg Equilibrium (HWE; P<1×10–6) or 
with no minor alleles in our dataset were excluded from subsequent analyses. In 
total, 661,354 SNVs were included in the eQTL analysis. 
 
 
4.4. Locus-based genetic analysis methods 
The study designs in Refs 1–3 included varied methods for genotyping genetic 
variants and quantifying gene and protein levels. A quick overview of different 
targeted methods used is given in Table 7. 
 
 
4.4.1. Genotyping  
To determine variants possibly affecting STC1, 13 tag-SNVs (Table 7) from the 
genic (12,893 bp) and promoter (2,672 bp, 5′ upstream) region were selected that 
captured additional 22 variants (r2>0.9). The variants were identified based on 
genotyping data from the 1000 Genomes Project (http://www.international 
genome.org/) for UTAH residents with Northern and Western European ancestry 
(CEU) as input for Haploview Tagger software (version 4.2) (Barrett et al., 2005). 
The 13-plex primers (Table S3 in Ref. 1) for the PCR and the extension were 
designed using MassARRAY® Assay Design 3.1 software. Positive and negative 
control samples and duplicate samples were included in every assay plate to 
assess the genotyping quality. The genotyping call rate was determined to be 
>95%, and all identified genotypes were in HWE (p>0.05). All 13 variants were 
genotyped for 366 REPROMETA maternal samples. REPROMETA placental 
samples (n=366) and FINNPEC maternal (n=1060) and fetal samples (n=874) were 
genotyped for three variants (rs12678447, rs3758089, rs3758086). 
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Table 7. Summary of utilized methods for locus-based analyses in the current thesis 
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Three variants [rs1150707 (ZSCAN9 c.568+1990 C>T); rs10044354 (ERAP2 
g.96984791 C>T) and rs11678251 (ALPG c.-318 G>A)] were genotyped using 
Sequenom MassArray® platform in a REPROMETA placental dataset (n=366) 
to validate the eQTL associations (Table 7). The variants were chosen based on 
the low false discovery rate (FDR), larger than two-fold expression difference 
between the heterozygote and major homozygote carriers, and link to protein-
coding gene. The primers for the 3-plex were similarly designed using the provided 
software. 
All multiplex genotyping was conducted using Sequenom MassArray® plat-
form (Sequenom, San Diego, CA, USA) according to the manufacturer’s protocol 
in all cases. 
Singleplex genotyping of selected variants was conducted using pre-made 
Taqman assays. 
The rs11678251 (ALPG c.-318 G>A) variant was genotyped in the HAPPY 
PREGNANCY placental samples (n=408) using a Taqman assay (ID 
C__27838320_10, Applied Biosystems, Foster City, CA, United States) (Table 7).  
Two variants (rs4769613 T/C, rs12050029 A/G) previously associated with 
PE were genotyped using Taqman assays (Applied Biosystems, Foster City, USA; 
Assay ID: C__32231378_10, C___1445411_10) in combined REPROMETA 
and HAPPY PREGNANCY placental sample set (n=2,097) and REPROMETA 
parental sample set (n=562) (Table 7). 
 
 
4.4.2 Taqman-assay based expression quantification 
The expression levels of ZSCAN9 (Hs00196838_m1), ERAP2 (Hs01073631_m1) 
and ALPG (Hs00741068_g1), as well as the neighboring genes ALPP 
(Hs03046558_s1), ERAP1 (Hs00429970_m1), and LNPEP (Hs00893646_m1), 
were determined using Taqman RT-qPCR gene expression assays according to 
manufacturer’s protocol (Table 7). The housekeeping gene Ubiquitin C (UBC, 
Hs00824723_m1) was used as a reference gene. Twenty-four individuals were 
chosen for each gene to represent genotypes for previously identified variants 
(rs1150707, rs10044354, rs11678251) equally when possible. 
 
 
4.5. Biomarker analysis from maternal blood 
Maternal plasma levels of STC1 protein were determined using enzyme-linked 
immunosorbent assay (ELISA) implemented by DuoSet ELISA kit (DY2958; 
R&D Systems) according to the manufacturer’s protocol (Table 7). STC1 levels 
were measured in 366 samples. All the measurements were performed in duplicate 
with each plate, including a reference sample for variability assessment. The 
estimated average intra-assay variability for processed ELISA plates (n=10) was 
4%, and respective inter-assay variability 7%. The details of the ELISA protocol 
have been discussed in Uusküla et al., 2012. 
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A set of commercially measured sFlt-1 levels in HAPPY PREGNANCY 
maternal plasma samples (n=153) was utilized for analyses (Table 7). Serum 
concentrations were retrospectively measured with a commercial immunoassay, 
B·R·A·H·M·S sFlt-1 Kryptor assay (Thermo Fisher Scientific) by the service 
provider Synlab Germany (Leinfelden, Germany). The measurement was done in 
immunofluorescent automated sandwich assays implemented on the KRYPTOR 
compact PLUS platform (#BM0106172) and using B·R·A·H·M·S reagents for 
the sFlt-1 assay (#845.075). Only samples drawn before term (<37th gestational 
week) and >1 week prior delivery were included in the analysis as sFlt-1 levels 
sharply increase before delivery (Palm et al., 2011) 
 
 
4.6. Bioinformatics and statistics 
4.6.1. Whole transcriptome cis-eQTL analysis and validation 
The analysis focused on proximal cis-eQTLs (±100 kbp from the gene start/end 
coordinates) as this region is likely to contain significant and functionally relevant 
eQTL hits (Veyrieras et al., 2008). Variant and gene coordinates were extracted 
using BioMart (Ensembl v54). Association analysis for eQTL discovery was 
conducted in Matrix eQTL package for R (Shabalin, 2012) using linear regression. 
The analysis was adjusted by the pregnancy outcome group (NORM, PE, SGA, 
LGA, GD), labor activity, and newborn sex. The test included 353,599 variants 
for a total of 659,826 tests. Nominal P-values were corrected for multiple testing 
using a built-in Benjamini and Hochberg method in Matrix eQTL. A statistically 
significant eVariant-eGene association was defined as FDR<0.05. For each 
identified eQTL, the proportion of gene expression variability explained by the 
variant was calculated (R2). 
In the RT-qPCR validation of selected variants, the analysis was conducted 
similarly with an additional covariate of gestational age. 
 
 
4.6.2. Genetic association testing 
In brief, all genetic association testing was carried out in PLINK, version 1.07 or 
1.9 (Purcell et al., 2007) either using an additive model with linear (newborn, 
maternal, or birth parameters) or logistic regression (case-control analyses). For 
each analysis, appropriate cofactors were included. All meta-analyses were 
combined under a fixed-effects model in PLINK or R. 
Mann-Whitney U test (MW) was used parallel with linear regression for testing 
the difference of maternal STC1 hormone and placental STC1 expression levels 
between minor allele carriers and major homozygote carriers of STC1 variants 
(Ref. 1). 
Association testing in REPROMETA with newborn parameters and three 
eQTLs (rs1150707, rs10044354, rs11678251) was implemented using both 
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additive and recessive models. Testing with infant postnatal growth was con-
ducted only under the recessive model. (n=7,669) cohorts. For the ALSPAC cohort, 
a proxy variant rs744873 was used in the analysis, obtained from the genome-
wide array dataset (Boyd et al., 2013) (Ref. 3). 
Analysis of preference in allele transmission from the rs4769613 T/C 
heterozygous parents was conducted using the χ2 test (Ref. 2). 
Analysis of rs4769613 and placental FLT1 expression utilized previously 
available RT-qPCR data (FLT1 and UBC levels) for 23 PE and 46 non-PE 
REPROMETA samples (Sõber et al., 2015). Gene expression levels were calcu-
lated using the 2–ΔΔCT method. FLT1 mRNA expression and sFlt-1 serum levels 
were transformed using log2 to resemble a normal distribution better. The dif-
ference in median FLT1 or sFlt-1 between PE and non-PE individuals was 
assessed using the Student t-test (Ref. 2). 
 
 
4.6.3. Functional profiling of placental eGenes 
Functional profiling analysis of eGenes identified in at least two of the three studies 
was conducted in the g:Profiler web server (version e100_eg47_p14_7733820 
(Reimand et al., 2016)). Terms were considered statistically significant at an 
adjusted P-value <0.05. 
 
 
4.7. Literature search on placental  
expression-modifying variants 
A literature search was conducted in PubMed using query: human and (placenta*) 
and (gene expression” or transcriptome”) and ( SNP” or SNV” or polymorphism” 
or eQTL”) not review and (y_10 [Filter])” (time of accession 31.08.2020). Articles 
that were not relevant (non-human subjects, no reported association testing 
between genetic variants and gene expression) were excluded. Only journal 





5.1. Candidate gene studies of genetic variants  
modulating placental gene expression and  
their link to pregnancy complications 
Two genes were selected for further investigation to determine the genetic 
variants coding for expression changes in PE. STC1 is a novel candidate gene for 
preeclampsia with no known expression-modulating variants. The second gene, 
FLT1, is a known gene implicated in PE with only recent insight into potential 
variants affecting its expression. 
 
 
5.1.1. The effect of genetic variants in  
the Stanniocalcin-1 locus (Ref. 1) 
The first study (Juhanson et al. 2016) aimed to comprehensively characterize STC1 
hormone and STC1 gene expression in human pregnancies, including in preg-
nancies complicated with PE. 
 
5.1.1.1. Placental and maternal variants affect gene and  
protein expression 
Three placental genetic variants (rs126788447, rs3758089, rs3758086) were tested 
for correlation with STC1 gene expression. One variant, rs126788447, signifi-
cantly affected the placental gene expression working as an eQTL (linear regres-
sion adjusted to the delivery mode and pregnancy complication group, P=0.014, 
Figure 5B). Another variant, rs3758089, showed lower STC1 expression in TT 
individuals, but the link was not statistically significant (P=0.067). Placental 
STC1 gene expression in REPROMETA samples (n=120) was not affected by 
maternal lifestyle (e.g., maternal age, gestational weight gain, etc.) or birth para-
meters (e.g., gestational age, newborn weight, etc.) (Supplementary Figure 4 in 
Ref. 1). 
Maternal STC1 hormone levels in REPROMETA maternal plasma samples 
(n=366) were similarly investigated with respective maternal variants. Variant 
rs3758089 (linear regression (LR) P=0.014, Mann-Whitney U (MW) test P=0.027) 
was significantly associated with maternal serum levels of STC1, but rs126788447 
had a significant association only with the MW test (P=0.034) (Figure 5A). As 
maternal STC1 levels were additionally affected by PE (MW P<0.01), delivery 
mode (MW P=0.01), smoking status (MW P=0.02), maternal age in non-PE 
individuals (LR P=0.05), and pre-pregnancy BMI (LR P<0.01) in PE individuals, 




Figure 5. Maternal (A) and placental (B) variants in the STC1 gene affect the serum 
hormone levels and placental gene expression, respectively. Linear regression testing 
association between genetic variants and maternal STC1 levels were adjusted for the 
presence of preeclampsia, delivery mode, maternal age, smoking status, and pre-
pregnancy BMI. Tests for gene expression were adjusted for the study group and delivery 
mode. LR, linear regression; MW, Mann-Whitney U test 
 
5.1.1.2. STC1 levels and genetic variants affect PE risk 
Maternal STC1 hormone level was significantly affected by PE status even after 
adjusting for other variables (delivery mode, smoking status, maternal age, and 
pre-pregnancy BMI, P=1.8×10–6). In contrast, placental mRNA levels were not 
significantly different in PE or non-PE individuals (P=0.49, Ref. 1 Figure S4A). 
However, it is not certain if maternal circulating STC1 is a reaction to PE or is a 
part of PE pathophysiology.  
As the genetic variants regulated STC1 protein and gene expression levels, it 
was also investigated if the genetic variants might affect the risk for developing 
PE. Maternal variants rs12678447 and rs3758089 were associated with PE risk 
in REPROMETA mothers (P=0.05, OR=2.8, 95% CI 0.99–7.85; P=0.01, OR=4.7, 
95% CI 1.39–15.96, respectively) (Table 8). To further investigate the association, 
the PE individuals were further divided into subgroups based on the time of the 
PE diagnosis, early-onset PE (<34th gestational weeks, EOPE), and late-onset PE 
(>34th gestational week, LOPE). Only LOPE risk was associated with rs3758089 
remained significant (P=0.04, OR=4.5, 95% CI 1.06–19.41, Table 8). Additional 
samples from the FINNPEC sample set (n=1220) were included in the meta-
analysis with the REPROMETA samples under the fixed effects model. How-
ever, neither genetic variants reached statistical significance in the expanded 






































































































































































































































































































































































































































































































































































































































5.1.2. The effect of genetic variants in  
the fms related receptor tyrosine kinase 1 locus (Ref. 2) 
The second study (Kikas et al., 2020) aimed to replicate the identified association 
and further investigate the variant effect on placental gene expression, maternal 
serum expression, and birth parameters. 
 
5.1.2.1. Variant rs4769613 near FLT1 as a risk factor for PE 
The C-allele of placental variant rs4769613 was significantly overrepresented in 
preeclamptic (n=96, 52.1%) compared to non-preeclamptic placentas (n=2001, 
43.6%, P=0.02). The CC homozygous genotype showed a similar tendency 
(26.0% vs. 18.5%, P=0.06) (Table 2 in Ref. 2). 
Analysis between variant alleles and PE risk identified an association in both 
REPROMETA (P=0.02, OR=1.91) and HAPPY PREGNANCY (P=0.04, OR=1.64) 
sample sets which was enhanced in the meta-analysis of the two datasets 
(P=0.002, OR=1.75) (Figure 6). Additional meta-analysis was carried out with 
previously reported data from five cohorts included in the published GWAS study 
(McGinnis et al., 2017). The combined meta-analysis improved the previously 
reported result (P=3.8×10–12, OR=1.22) (Figure 6). However, parental genotypes 
of rs4769613 did not show any association with PE risk in REPROMETA samples. 
 
Figure 6. Association of rs4769613 placental genotypes with risk for developing PE. 
Meta-analysis with Estonian sample sets REPROgrammed fetal and/or maternal META-
bolism (REPROMETA), and Development of novel non-invasive biomarkers for fertility 
and healthy pregnancy (HAPPY PREGNANCY) included 96 preeclampsia (PE) cases 
and 2001 non-PE pregnancies. The combined meta-analysis included 5 European cohorts 
from the published genome-wide association study meta-analysis (PE cases, n=4476; 
non-PE, pregnancies, n=312239, Table S4 in Ref. 2) in addition to the Estonian sample 
sets. Association testing was carried out using logistic regression adjusted to newborn sex 





Notably, the placental risk variant is specific to PE and is not associated with other 
tested late pregnancy complications (gestational diabetes, small- and large-for-
gestational-age newborns) neither in REPROMETA nor HAPPY PREGNANCY 
sample sets. Overall, the variant was not associated with birth and newborn para-
meters such as weight, length, placental weight, and gestational age. However, 
pregnancies with CC-genotype placentas developed PE about two weeks later 
than CT- and TT-genotype carriers (P<0.05). 
 
5.1.2.2. Variant rs4769613 near FLT1 represents  
a potential conditional eQTL 
To further investigate the effect of the placental risk variant on phenotype, the 
placental FLT1 gene expression and maternal serum levels of sFlt-1 were targeted. 
Even though no linear association was found with either, the FLT1 expression was 
significantly higher in PE placentas with the CC-genotype compared to CT/TT-
genotype (P=0.05) (Figure 7, Figure 2 in Ref. 2). The same trend was not present 
in non-PE placentas, indicating possible conditional gene expression regulation 
in preeclamptic pregnancies. 
 
 
Figure 7. Placental gene expression of FLT1 is upregulated in preeclampsia placentas (PE) 
compared to non-preeclampsia placentas (NPE), especially in PE placentas with CC-






5.1.3. Review of placental eQTLs in candidate  
gene based studies (Ref. 4) 
As a part of the doctoral thesis, a systematic analysis was conducted of placental 
eQTLs identified in candidate gene analyses. The search query and filtering 
principles have been detailed in the Methods. It was found that in the last decade, 
only ten studies have been carried out that met the criteria (Table 9). However, 
the design of these studies for eQTL analysis is quite diverse, and some included 
placental samples also from complicated pregnancies (most commonly PE). The 
tissue samples themselves also vary by site, either including full-thickness placenta 
or more specific regions, making it hard to conclude the universality of these 
results in the placenta. Almost all these associations represent cis-eQTLs, either 
in genic (eGenes ABCG2, FKBP5, CXCR3, STC1, HIF1A, P21, LEPR) or nearby 
regulatory regions (SERPINA3, FLT1) with only one variant located on another 
chromosome (miR-518b). No variants have been identified as eQTLs in other 
tissues except for SERPINA3 and LEPR eVariants, according to the GTEx 
database. However, rs1360780 and rs9436746 also regulate the mRNA splicing 
of FKBP5 and LEPR, respectively. 
 
 
5.1.4. Take home message from candidate genes studies  
of genetic variants modulating placental gene expression and  
their link to pregnancy complications 
For the first time, the maternal and fetal modulators of maternal plasma STC1 
and placental STC1 expression were characterized in pregnancy. The link between 
STC1 levels and PE was confirmed, and two new genetic PE risk variants, 
rs12678447 (A/G) and rs3758089 (T/C), in the STC1 gene were identified. 
Placental variant rs4769613 near the FLT1 gene is the only genetic PE-
specific risk factor validated in several independent cohorts. No association with 
PE risk was found with maternal or paternal rs4769613. The variant possibly 
represents a conditional eQTL, affecting enhancer response due to unfavorable 
placental conditions. However, no effect was seen on maternal serum levels of 
sFlt-1. 
The two studies provided excellent in-depth analyses of the candidate genes 
and provided novel placental eQTLs. As the number of candidate gene studies 
addressing expression-modulating variants is limited, these were a needed 




















































































































































































































































































































































































































































































































































































































































































































































































5.2. Whole-genome screening of placental eQTLs (Ref. 3) 
I aimed to map placental variants that affect gene expression and potentially 
pregnancy course. To investigate robust eQTLs in the placenta, we included 
samples from different pregnancy outcomes (PE, SGA, LGA, GD, NORM, n=8 
each group) from available datasets (Kasak et al., 2015; Sõber et al., 2015) and 
focused on nearby variants, i.e., cis-eQTLs. The region of interest for cis-eQTLs 
was limited to 100 kbp from the start or end of the gene to exclude possible 
sporadic associations, including the intragenic region, only genes with a median 
expression >100 normalized read counts were included and associations with 
FDR<5% were considered significant. Details of the study design have been 
discussed in paragraph 5.2.4. and in Table 11. The final analysis included 11,733 
genes and 353,599 variants. 
 
 
5.2.1. Distribution of eQTLs in the placenta 
The study identified 199 eSNV-eGene associations, including 88 independent 
variants (LD r2<0.8) affecting 63 placental genes. Variants were detected across 
the genome, excluding only four smaller chromosomes (chr18, 20, 21, and Y, 
Figure 8A, Figure S2 in Ref. 3). On average, the proportion of gene expression 
explained by the eQTLs was 0.52 (R2 range 0.45–0.77, Figure 8B).  
ZSCAN9 gene had the most eQTLs (seven independent signals) associated 
with its expression levels. This gene was also the top two result among protein 
coding eGenes (FDR P=9.7×10–7), only marginally surpassed by RPL9 (FDR 
P=9.7×10–7) (Table 3 in Ref. 3). Three top protein coding eGenes with expression 
change >2 fold (ZSCAN9, ERAP2, ALPG) were selected for further validation in 
an independent sample set (Figure 3 in Ref. 3). Only ALPG did not reach the 
statistical significance level during validation, possibly due to lower minor allele 
frequency. 
Placental eGenes were had primarily moderate to high gene expression in the 
placenta (Figure 8C), but only two (PSG7, ALPG) had placenta enriched protein 
expression according to the Human Protein Atlas (proteinatlas.org) (Figure 1 in 
Ref. 3). Identified eGenes were associated with a wide array of functional 
categories, most commonly with cellular transport (n=10) and cell structure 
(n=10) (Table 5 in Ref. 3). Almost 10% of eGenes were linked to immunity-
related functions, known to be important in pregnancy maintenance. 
Among the identified eGenes, 13 (10 protein coding, 3 pseudogenes) were 
previously undetected by other genome-wide investigations into placental eQTLs 
(Table 10). In addition to ZSCAN9, novel eGene TLDC1 was also among the top 
protein coding eGenes (FDR P=4.1×10–4). The GTEx database did not report four 











Figure 8. Genome-wide placental eQTL analysis outcomes. A) Manhattan plot of 
identified P-values from the discovery analysis. The P-values of selected eSNPs-eGene 
pairs are shown in green (discovery) and blue (validation analysis). The red line indicates 
the chosen statistical significance threshold (FDR 5%). B) The proportion of eGene 
expression (R2) explained by the detected eSNPs. C) The expression levels of identified 
placental eGenes (in read counts). Modified from Ref. 3. 
 
 
5.2.2. Associations with pregnancy complications and  
newborn parameters 
All identified placental eQTLs were tested for association with pregnancy 
complications, but none reached statistical significance following multiple testing 
correction. Top variants selected for validation were also analyzed for a link to 
newborn and birth characteristics in REPROMETA samples. ERAP2 and ZSCAN9 
variants were not associated with any parameter, excluding nominal connection 
of ZSCAN9 variant rs1150707 and placental weight with the recessive model 
(P=0.04, Table 4 in Ref. 3). In contrast, ALPG variant rs11678251 was associated 
with several parameters, including birth weight, placental weight, chest circum-
ference, and postnatal child weight and height at 6 months (Figure 9). These links 
were further explored in two additional cohorts – HAPPY PREGNANCY and 
ALSPAC. However, the result was not replicated in the other sample sets, and 







Figure 9. Association of ALPG rs11678251 with newborn and child growth parameters. 
 
 
5.2.3. Comparison of published genome-wide placental eQTL 
association studies (Ref. 4) 
Three hypothesis-free genome-wide eQTL mappings have been conducted to 
date (Delahaye et al., 2018; Peng et al., 2017; Kikas et al., 2019). These studies 
detected 3218, 985, and 199 cis-eVariant-gene links with 3218, 615, and 63 genes 
affected (eGenes), respectively. As the study design differs in each analysis, the 
raw results cannot be compared robustly. In addition, Peng et al. only reported 
one cis-eQTL per gene. However, the number of identified eQTL associations 
reflected the stringency of the study design and the sample size (Table 11).  
Only 18 eGenes were detected in all three studies (Table 12), and additional 
367 eGenes overlapped in at least two of the studies. These robust eGenes were 
enriched for several gene ontology (GO) terms, including “transmembrane trans-
porter”, “ATPase activity”, and immunity-related Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways, such as “allograft rejection” or “graft-versus-host 








































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 12. An overview of placental eGenes identified in all three genome-wide eQTL 
studies, based on Ref 4 (Kikas et al., 2021) 
Gene Phenotypes associated with 




Chronic kidney disease (Choma et al., 2016; B. Han et al., 2019) 
Obesity (Frühbeck et al., 2020)
Survival in cancers (Chetry et al., 2018; Thapa et al., 2018; L. 
Zhu et al., 2019)
Sperm function (Laforenza et al., 2017)
ATG10 
Cancer treatment efficacy (Sun et al., 2020)
Cancers (Shen & Lin, 2019)
age of menopause (Bae et al., 2019)
Amyotrophic lateral sclerosis (Vats et al., 2018)
CYREN  Immune response to smallpox 
vaccine 
(Kennedy et al., 2012) 
CEP72  
Cancer (X. D. Li et al., 2019)
Drug response (Geng et al., 2018; Stock et al., 2017) 
DCTN5  Favorable prognosis in 
melanoma 
(Q. Wang et al., 2018) 
DDX11  
Warsaw Breakage Syndrome (van der Lelij et al., 2010)
Cancers (J. Li et al., 2019; Park et al., 2020) 
ERAP2 
Cancers (C. Li et al., 2020; Wu et al., 2020) 
Arterial stiffness, hypertension (Logan et al., 2020; Zee et al., 2018) 
Immune-related diseases (Cortes et al., 2013; Kuiper et al., 2014; 
Yin et al., 2015)
Preeclampsia (Seamon et al., 2020)
Susceptibility to infectious 
diseases 
(Saulle et al., 2020) 
FAM118A 
Ankylosing spondylitis (Robinson et al., 2016)
Glioblastoma  (Stangeland et al., 2015)
GUCY1B2 Bipolar disorder (Djurovic et al., 2010)
HEATR5A Preeclampsia (Jacobo-Baca et al., 2020)
HTR7P1 NA 
IP6K3  
Inflammatory bowel disease (Frenkel et al., 2019)
Hashimoto’s thyroiditis (Brčić et al., 2019)
Late-onset Alzheimer’s disease (Crocco et al., 2016)
PSG7 Trophoblast differentiation (Camolotto et al., 2010)
PSMD5 Colorectal tumor progression (Levin et al., 2018)
SPSB2 Indicator of oocyte aneuploidy (Fragouli et al., 2012)
ZNF100 Ovarian cancer survival (Glubb et al., 2017)
TRIM66 Cancers (Cao et al., 2020; Chen et al., 2015; Zhan 
et al., 2015)
WDR91 Neuronal development in mice (K. Liu et al., 2017)
Full gene names are available in Abbreviations. 
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Peng et al. demonstrated enrichment of placental eQTLs among GWAS loci for 
birth weight, childhood obesity, and adult diseases in general. The highest enrich-
ment was detected among GWAS loci linked to metabolic traits (e.g., total 
cholesterol), neurological (e.g., Alzheimer’s disease), and immunological diseases 
(e.g., asthma). This enrichment was not replicated in the other studies, but a 
fraction of placental eQTLs (1–3%) were listed as GWAS loci for adult disorders 
in similar categories. Variants near ERAP2, an eGene detected in all the studies, 
have been previously linked to various diseases, such as PE, hypertension, and 
immune-related diseases (Table 12). 
 
 
5.2.4. Take home message from genome-wide eQTL screening  
in the placenta 
My study was one of the first genome-wide studies to address placental eQTLs, 
identifying almost 200 robust variants in the near vicinity of genes expressed in 
the placenta. Placenta-specific eQTLs are of interest as these could be potential 
candidates for further research in pregnancy complications. For example, ALPG 
eQTL exhibited a potential effect on newborn and child weight in the initial 
analysis. Placental eQTLs could also have implications for adult diseases and 
traits, as all placental genome-wide eQTL studies so far have demonstrated co-
localization of placental variants with GWAS loci.  
A list of about 400 robust placental eGenes was enriched for several GO terms, 
including allograft rejection” that could be linked to maternal tolerance of the 
fetus. However, the designs of the three studies varied greatly, and therefore some 




6.1. Expression quantitative trait loci as unrecognized 
genetic risk factors for human disease 
Historically, considerable focus in genetic studies on human rare diseases has 
been on exonic variants. As these can result in a change in protein structure, the 
link to the phenotype is easily predicted and possible to experimentally validate. 
Reasons behind associations with variants in non-coding regions are more 
challenging to pin down and are often excluded from the analysis from the start. 
However, the coding variants make up only about 0.5% of all short sequence 
variants mapped in the human genome (Marian, 2020). With the emergence and 
widespread use of genome-wide association studies (GWAS), more intergenic 
variants have been linked with various diseases and traits. About 80% of asso-
ciated variants in complex diseases are located in non-coding regions (Suzuki et 
al., 2019). In parallel, more information is becoming known about these regions 
enabling more accurate variant effect prediction.  
Disease-linked variants in non-coding regions are thought to exert their effect 
through either enhancers/suppressors or causing instability in the mRNA. Several 
studies have shown an enrichment of expression quantitative trait loci (eQTLs) 
among GWAS loci (Table 5), providing the missing link between single nucleotide 
variants and associated phenotypes. As many eQTLs are tissue- or even cell-type 
specific, the data could also provide additional information about the cell types 
and tissues central to the pathophysiology of the disease. For example, a study 
applying eQTL effect directions derived from analyses conducted in fractioned 
immune cell populations, identified an involved cytokine pathway significantly 
activated in CD4+ T cells in rheumatoid arthritis data set (Ishigaki et al., 2017). 
Identifying eQTLs in the tissue of interest is crucial because of tissue-specificity, 
using data from other tissues will not produce an accurate result.  
Even though more studies have been published in recent years focusing on 
placental variants affecting gene expression, the subject is still underexplored. 
Placental function has been previously implicated in adult health through fetal 
programming in utero (Bonnin et al., 2011; Longtine & Nelson, 2011), a concept 
known as the Developmental Origins of Health and Disease (DOHaD) (Barker & 
Osmond, 1986). It has been also demonstrated that genes specifically expressed 
in the second trimester are associated with adult health outcomes (Uusküla et al., 
2012). Placental eQTLs have a part in regulating the uterine environment through 
placental gene expression and potentially affecting fetal programming. Many of 
the eGenes identified in all genome-wide placental eQTL studies were associated 
with adult diseases, most commonly cancer (n=10/18) but also several complex 
diseases such as hypertension (ERAP2) and obesity (AQP11). Also, GWAS loci 
for adult traits as well as birth weight and childhood obesity are enriched among 
placental eQTLs (Peng et al., 2017, 2018). Still, it is unlikely that a single eQTL 
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could strongly affect fetal growth as the trait is highly multifactorial and dependent 
on non-genetic factors such as maternal nutrition (Warrington et al., 2019).  
Apart from affecting the newborn’s future health, placental eQTLs also can 
affect the risk for pregnancy complications. I identified few nominal associations 
among placental eQTLs with risk to gestational diabetes, small-for-gestational-
age newborns, and large-for-gestational-age newborns. The lack of robust asso-
ciations may be due to the eQTL analysis design. As different phenotypes included 
had known differences in gene expression profiles, the pregnancy complication 
group was used as a cofactor. This could have led to filtering out variants with 
stronger links to any pregnancy complication. Conducting further analysis would 
be warranted to investigate these links between eQTLs and pregnancy compli-
cations. Some identified placental eQTLs have already been previously asso-
ciated with pregnancy complication risk. Placental eQTL rs2549782, a missense 
variant in ERAP2, has been associated with PE in Australian and African Ameri-
can populations (Hill et al., 2011; Johnson et al., 2009). Additionally, variant 
rs9478812 that was strongly linked to PE in a recent study (K. J. Gray et al., 2021) 
is located in the intron of a robust placental eGene PLEKHG1. However, the 
variant itself is only in mild linkage disequilibrium with identified eVariants 
(rs7738394 (Kikas et al., 2019), rs55646755 (Peng et al., 2017) r2=0.1 in CEU 
population, Ensembl v103 http://www.ensembl.org/). Several studies con-
centrating on candidate genes have identified additional placental eQTLs, 
including for STC1 (Ref. 1) and FLT1 (Ref. 2). The FLT1 variant rs4769613 had 
a robust link to PE risk. 
 
 
6.2. Limiting factors in current placental eQTL studies and 
further studies 
Genome-wide placental eQTL analyses have provided a list of potential candidate 
genes and variants that can be focused on in future research of pregnancy compli-
cations. However, the current list of robust eGenes is relatively short due to 
different study designs and small sample sizes. Moreover, the identified variants 
for most eGenes were unique among the studies. This is most likely due to small 
statistical power as about 400 individuals would be needed for adequate power 
for genome-wide cis-eQTL analysis (power 0.8 for variants with MAF≥5% and 
effect size ≥standard deviation) (Dong et al., 2021, https://bwhbioinfo. 
shinyapps.io/powerEQTL/). A meta-analysis of all three current placental eQTL 
studies, and any future ones, could increase the analysis power and the list of 
robust results. Currently, the genome-wide eQTL studies were unable to replicate 
the variants identified in placental candidate gene studies. This suggests there is 
still a need for fine-mapping of candidate gene genetic modulators as these types 
of studies usually have more power to detect more minor effects.  
In addition, as demonstrated by Ref. 2, not all eVariants are detectable in all 
sample sets if the effect is brought on by some trigger (i.e., conditional eQTLs) 
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or a particular timepoint in development (i.e., dynamic eQTLs). Future analyses 
focusing on certain clinical sample sets or placental samples from the first and 
second trimester of pregnancy could provide additional insight into placental 
regulation in normal and complicated pregnancies. 
As described previously, the placenta consists of various cell types already in 
early pregnancy (Y. Liu et al., 2018; Vento-Tormo et al., 2018). When using a 
whole-thickness sample, it cannot be separated which cells are the original source 
of the signal. Opposite effects on gene expression in different cell types might 
complicate the detection of associations. This limitation could be tackled in two 
ways in future studies. First, separating cells by type, followed by DNA and RNA 
extraction and analysis. However, this approach is work- and funding-intensive. 
The second option would be to take the known proportions of placental cell types 
into account when conducting the analysis using available tools (Jew et al., 2020; 
Newman et al., 2015). Recently, methylation profiles for five main placental cell 
types were generated to be used as reference for deconvolution (Yuan et al., 
2021), but no reference of placental cell composition based on gene expression 
has been published to date. 
Another complicating factor is confined placental mosaicism. Placental tissue 
includes many clonal populations of trophoblast cells due to fast proliferation in 
placental development. It has been shown that the placenta can include chromo-
somal aberrations, copy number variants (CNV), and single nucleotide substi-
tutions that are not present in the fetus (Coorens et al., 2021; Kasak et al., 2015). 
The placental genomic landscape was comparable to childhood cancer regarding 
mutation burden (Coorens et al., 2021). Each bulk sample taken from a single 
placenta can represent a clonal expansion. On average, placental samples included 
145 substitutions, and almost half of the samples included a CNV. The effect of 
placental somatic changes on the transcriptome is still unexplored. As even gross 
chromosomal changes present do not change placental gene expression linearly 
(Bianco et al., 2016; Lim et al., 2017; Rozovski et al., 2007), comprehensive 
studies are needed to address the topic. 
 
 
6.3. Clinical implications of the study –  
the potential of applying novel genetic risk factors  
to screen and identify high-risk pregnancies 
Many genes have been associated with PE, either by gene or protein expression 
changes. However, the genetic reasons behind the alterations are often still 
unknown. Identifying the cause can provide insight into the pathology of PE and 
potentially provide targets for treatment. 
The assessment of FLT1 variant rs4769613, first identified by McGinnis et al. 
and replicated in the Estonian cohort in the current doctoral project, could be a 
valuable addition to the current risk assessment protocol for PE. The FLT1 variant 
is the first PE-associated genetic marker that has been consistently associated 
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with PE in several independent sample sets from different populations (Kikas et 
al., 2020; McGinnis et al., 2017; Steinthorsdottir et al., 2020). The C-allele of the 
variant increases the odds of developing PE 1.2 times. Notably, the variant is 
linked to late-onset PE in particular and does not affect the risk of other late preg-
nancy complications, making the interpretation more straightforward. Currently, 
the main obstacle to adding fetal variants as biomarkers is obtaining fetal genomic 
material. 
Until recently, fetal DNA was only obtainable through amniocentesis or 
chorionic villus sampling. These are invasive procedures that carry a 0.1–0.2% 
risk of fetal loss (Odibo & Acharya, 2020). For this reason, these are only used if 
either first-trimester screening shows a high risk for aneuploidy or after an 
abnormal ultrasound. In recent years, non-invasive prenatal testing (NIPT) has 
been incorporated into a clinical routine in Estonia that allows testing the fetal 
genome from maternal blood. The method is based on detecting cell-free fetal 
DNA (cffDNA) that originates from the placenta. CffDNA was first detected in 
the maternal serum in 1997 (Dennis Lo et al., 1997). Currently, it is used in clinics 
to detect common chromosomal abnormalities (trisomies 21, 13, 18) and micro-
deletion syndromes (e.g., 22q11.2 and 1p36 deletions). However, it has been 
shown to be able to determine fetal single nucleotide variants for monogenic 
diseases (L. S. Chitty et al., 2011; Lyn S. Chitty et al., 2013; Zhang et al., 2019). 
As the methods for cffDNA extraction constantly improve, in future, genotyping 
fetal genetic risk variants could be done during routine blood draw. 
Most biomarkers used in current clinical practice for PE risk assessment are 
reactionary to some fault in pregnancy, such as hypertension or sFlt-1 rise in PE. 
Both of these are present only slightly before the onset of PE. On the other hand, 
fetal genetic risk could be already determined in the first trimester with NIPT. 
Using placental and maternal factors in a combined manner would enable more 
precise classification of high-risk pregnancies as early as possible.  
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7. CONCLUSIONS 
The current doctoral thesis investigated placental genetic variants that modify 
gene expression and could be potential risk factors for pregnancy complications. 
The results can be summarized as follows: 
 
1. Systematic assessment of preeclampsia-associated hormone stanniocalcin-1 
determined that STC1 levels were modified by several maternal characteris-
tics, e.g., maternal smoking and delivery mode. Fetal variant rs12678447 was 
identified as an eQTL, modifying placental STC1 mRNA expression. How-
ever, only maternal rs12678447 was associated with late-onset preeclampsia 
in a meta-analysis combining Estonian REPROMETA and Finnish FINNPEC 
sample sets. 
 
2. Placental variant rs4769613 located upstream of FLT1 was confirmed to 
increase preeclampsia risk during pregnancy. The FLT1 variant was not 
associated with any other late pregnancy complication or newborn parameters. 
In preeclamptic placentas, rs4769613 CC homozygotes had significantly 
increased FLT1 gene expression than CT/TT genotype carriers. The variant 
did not have any effect on the levels of sFlt-1 in the maternal serum. 
 
3. Third ever placental eQTL screen was conducted focusing on variants in the 
immediate vicinity of genes. Utilizing several filters to exclude spurious results, 
199 variant-gene associations were detected. These affected the expression of 
63 eGenes, of which 13 were previously unknown for the placenta. Among 
the identified placental eVariants, few had a suggestive association with either 
pregnancy complication or newborn parameters.  
 
4.  Robust eGenes that were identified in at least two studies (n=417) were enriched 
for several GO terms such as “transmembrane transporter”, “organelle mem-
brane” but also “allograft rejection”. This illustrates that the identified eGenes 
are not random. The current data is a good starting point for further research 
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SUMMARY IN ESTONIAN 
Platsenta geeniekspressiooni ning raseduse kulgu mõjutavad 
ühenukleotiidsed variandid 
Platsenta on unikaalne organ, mis eksisteerib inimkehas ainult raseduse ajal. 
Platsental on oluline roll ema ja loote vahelise toit- ja jääkainete vahetuses, lisaks 
toodab platsenta mitmesuguseid makromolekule, mis mõjutavad raseduse kulgu. 
Platsenta tekib juba esimesel trimestril, kui tsütotrofoblasti rakud tungivad ema 
endomeetriumi, ning saab küpseks pärast 11. rasedusnädalat. Platsenta arengu-
häired võivad tekitada erinevaid tüsistusi – liiga sügava invasiooni korral tekib 
placenta accreta, mille korral platsenta ei eraldu pärast lapse sündi ning sünnitus 
tüsistub tugeva verejooksuga. Liiga vähese invasiooni korral tekib loote kasvu-
peetus, preeklampsia ning suureneb risk platsenta enneaegseks irdumiseks. 
Platsenta kasv ja areng peab olema täpselt reguleeritud, et vältida tüsistuste teket 
raseduse jooksul. 
Preeklampsia (PE) avaldub raseduse teisel poolel uustekkelise arteriaalse 
vererõhu tõusuna, millele lisanduvad ema organite kahjustuse või platsentaarse 
puudulikkuse sümptomid. Paljudel juhtudel lisandub proteinuuria, kuid võib 
esineda ka maksakahjustus, neuroloogilised sümptomid, loote kasvupeetus ja 
teised sümptomid. PE esineb Eestis alla 2% (1.7% 2019. aastal), kuid mitmel pool 
maailmas on esinemissagedus kuni 5% rasedate naiste hulgast. Tänu tervishoiu 
arengule on arenenud maades PE suremus madal, kuid see on jätkuvalt kõrge 
arengumaades, kus igal aastal sureb PE tõttu üle 60 000 naise. Preeklampsia 
tekkeks on väga oluline platsenta roll. On teada, et platsenta geeniekspressiooni 
profiil muutub suurel määral PE korral. Platsenta eemaldamine on ainuke lõplik 
ravi PE puhul ning rasketel juhtudel tuleb esile kutsuda enneaegne sünnitus, 
millega kaasnevad riskid lapsele. 
Üheks platsenta geeniekspressiooni võimalikuks regulaatoriks on geeni-
ekspressiooni mõjutavad geneetilised variandid (expression quantitative trait 
loci, eQTL, eVariant). Selliste variantide geeniekspressiooni mõjutavat efekti on 
näidatud paljudes inimese kudedes. Suurimaks sellekohaseks uurimuseks on 
GTEx projekt, mis sisaldab andmeid umbes 5 miljoni variandi kohta 49 koes. 
Platsenta koes on eQTL-sid ülegenoomselt uuritud vaid kahe teadustöö raames. 
Kuna aga suur osa variante mõjutavad ekspressiooni vaid kindlates kudedes, on 
oluline eQTL-sid uurida just huvipakkuvas koes. Usaldusväärsete platsenta 
eGeenide tuvastamine võimaldab paremini mõista platsenta dünaamika regu-
latsiooni ning pakub uusi kandidaatgeene rasedustüsistuste uuringuteks. 
Käesolevas doktoritöös on antud lühiülevaade inimese rasedusest, platsentast 
ning sagedasematest rasedustüsistustest. Pikemalt on käsitletud preeklampsia 
geneetikast ning koondatud on praegused teadmised eQTL-idest platsentas hai-
guste kontekstis. 
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Antud doktoritöö põhieesmärk oli kirjeldada platsenta geneetiliste variantide 
mõju geeniekspressiooni regulatsioonile ning rasedustüsistuste tekke riskile. 
Selleks sõnastasime kolm spetsiifilist eesmärki: 
 
1.  Uurida preeklampsia kandidaatgeenide, STC1 ja FLT1, ekspressiooni mõju-
tavaid geneetilisi variante. 
2.  Leida ja iseloomustada ülegenoomsel uuringul eQTL-d platsenta koes. 
3.  Koostada terviklik ülevaade kirjanduses tuvastatud platsenta eQTL-dest nii 
kandidaatgeenide kui ülegenoomsetes uuringutes. 
 
 
Uuritavad ja meetodid 
 
Esimese kahe eesmärgi täitmiseks kasutati emadelt ja platsentadest võetud proove 
eesti REPROMETA (REPROgrammed fetal and/or maternal METAbolism) ja 
HAPPY PREGNANCY (Development of novel non-invasive biomarkers for 
fertility and healthy pregnancy) valimitest. Mõlemad valimid koguti koostöös 
Tartu Ülikooli Kliinikumi naistekliinikuga vastavalt 2006–2011 ning 2013–2015. 
REPROMETA uuringu puhul kaasati indiviidid uuringusse rasedustüsistuse 
avaldumise (preeklampsia, PE; gestatsiooniea kohta suured ja väiksed vast-
sündinud, LGA, SGA; gestatsiooni diabeet, GD; või ilma kaasuva tüsistuseta 
kontrollid, NORM) ajal vahetult enne või pärast sünnitust. HAPPY PREGNANCY 
uuringusse kaasati naised, kes pöördusid rasedusaegsele jälgimisele esimesel 
visiidil ning kelle raseduse kulgu jälgiti kuni sünnituseni. Doktoritöös teostatud 
uuringu jaoks jagati indiviidid HAPPY PREGNANCY valimis sarnaste põhi-
mõtete järgi alagruppideks kui REPROMETA valimis.  
PE diagnoositi juhtudel, kui süstoolne vererõhk ≥140 mmHg ja/või diastoolne 
vererõhk ≥90 mmHg, millele lisandus proteinuuria ≥3g 24 tunni uriinis või 
neuroloogilised sümptomid. PE-ga indiviidid jagati varase (<34. gestatsiooni-
nädalat) ja hilise algusega PE (>34. gestatsiooninädalat) alagruppidesse vastavalt 
sümptomite tekke ajale. GD diagnoositi kui glükoosi taluvustestil oli vereplasma 
glükoosi tase enne glükoosi manustamist >5.1mmol/l ja/või >10.0mmol/l ja /või 
>8.5mmol/l vastavalt 1ja 2 tundi pärast 75g glükoosi manustamist. LGA ja SGA 
diagnoositi kui vastsündinu kaal oli vastavalt >90 või <10 protsentiili lapse soole 
ja raseduskestusele kohandatud kasvukõveral (Sildver et al., 2015). NORM juhud 
defineeriti kui rasedused, kus ei esinenud eelnevalt mainitud rasedustüsistusi. 
Uuringud oli eelnevalt heaks kiitnud Tartu Ülikooli Inimuuringute Eetika-
komitee (protokollid 146/18, 27.02.2006; 150/33, 18.06.2006; 158/80, 26.03.2007; 
221/T-6, 17.12.2012; 286/M-18, 15.10.2018) 
Lisaks Eesti valimitele oli kaasatud doktoritöö raames tehtud uuringutesse 
FINNPEC (kogutud 2008–2011 Soomes, Jääskeläinen et al., 2016) ning ALSPAC 
(kogutud 1991–1992 Ühendkuningriigis, (Boyd et al., 2013; Fraser et al., 2013)) 
valimid. 
Statistiliseks analüüsiks kasutati programmi PLINK (Purcell et al., 2007) ja R 
paketti Matrix eQTL (Shabalin, 2012). 
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Uurimistöö tulemused ja järeldused 
 
1. STC1 hormooni tase ema veres seostus sünnitusviisi ja suitsetamisega nii PE 
kui ka ilma PEta mittetüsistunud raseduste korral. Ema vanus seostus hor-
mooni tasemega ilma PE-ta raseduste korral ning raseduseelne KMI ainult 
PEga tüsistunud raseduste korral. STC1 geeni ekspressiooni tase seostus loote 
variandiga rs12678447. Nii Eesti REPROMETA kui Soome FINNPEC vali-
mite meta-analüüsis seostus ainult emapoolne rs12678447 preeklampsia riski 
tõusuga (šansside suhe 1.38). 
2. Uuringu tulemusena kinnitus FLT1 geenist ülesvoolu asuva variandi rs4769613 
seos PE riskiga. Teiste testitud rasedustüsistuse ega lapse sünniparameetritega 
eelnimetatud variant ei seostunud. FLT1 ekspressiooni tase oli oluliselt 
kõrgem neis PE tüsistunud rasedustest pärinevatest platsentades, mis kandsid 
rs4769613 CC genotüüpi võrreldes CT ja TT genotüübi kandjatega. FLT1 
variandi määramine võib olla abistavaks markeriks kliinikus kasutatavates 
preeklampsia riski ennustamise mudelites.  
3. Doktoritöö projekti raames läbiviidud ülegenoomsel platsenta eQTL-de uurin-
gus tuvastasin 199 usaldusväärset geenilähedast varianti, mis mõjutavad 63 
geeni ekspressiooni platsentas. Neist 13 olid kirjeldatud platsentas eGeenina 
esmakordselt. Mõned platsenta eQTL-dest seostusid pilootvalimis ka rasedus-
tüsistuse või lapse sünniparameetritega. 
4. Kolme seni läbiviidud platsenta eQTL-de uuringu alusel on 16 valku 
kodeerivat geeni, mis on tuvastatud läbivalt kõigis kolmes uuringus. Vähemalt 
kahes uuringus tuvastatud eGeene oli 417 ning nende funktsionaalsete radade 
analüüsil ilmnes rikastatus mitmete GO radadega, näiteks „transmembraanne 
transporter”, „organelli membraan” ning „transplantaadi äratõukereaktsioon”. 
Doktoritöö raames koostatud ülevaade on hea lähtepunkt tulevastele uurimus-





I would like to express my deepest gratitude to 
 
− Professor Maris Laan, my principal supervisor, for her expert advice, patience, 
constructive feedback as well as support and encouragement throughout not 
only my Ph.D. studies but also as a novice BSc student just starting in science; 
− Associate professor Kristiina Rull, my supervisor, for her kind support and 
advice, especially regarding pregnancy complications; 
− my referees Triin Laisk and Külli Kingo for positive feedback and construc-
tive comments on the critical review of my thesis; 
− all my current and past colleagues from the Human Genetics research group 
for providing an inspiring working atmosphere. Special thanks to Rain Inno 
and Laura Kasak for always being supportive and providing great scientific 
discussions; 
− my dear friend Diana for providing support and linguistic help throughout my 
studies; 
 
Finally, my greatest appreciation goes to my family and friends for their patience 




This work was supported by the grants from Estonian Research Council (IUT34-
12, PRG1021), the European Union through the European Regional Development 
Fund (project HAPPY PREGNANCY, 3.2.0701.12-0047), and PER ASPERA 
(2014–2020.4.01.16-0027; grant holder: University of Tartu) as well as personal 
stipends from Archimedes Foundation, Graduate school in Biomedicine and 


















Name:  Triin Kikas 
Date of Birth: 7th of November 1991 




2010–2013 BSc in Gene Technology, Faculty of Science and Technology, 
University of Tartu 
2013–2015 MSc in Biomedicine, Faculty of Science and Technology, Uni-
versity of Tartu 




2019–present Junior lecturer of Human Genetics, Institute of Biomedicine and 
Translational Medicine, University of Tartu 
2019–2020 Junior research fellow in Biomedicine and Translational 
Medicine, Institute of Biomedicine and Translational Medicine, 
University of Tartu 
 
Supervised dissertations 
2019 Käbi-Riin Ojassoo, BSc in Gene Technology, supervisors: Triin Kikas, 
Mario Reiman, Mihkel Vaher; Alternative splicing in normal and 
preeclamptic pregnancies; Faculty of Science and Technology, University 
of Tartu. 
2019 Külliki Matt, MSc in Pharmacy, supervisors: Kristiina Rull, Triin Kikas; 
Association of FLT1 gene polymorphism to preeclampsia and other 
gestational hypertensive diseases and the need for antihypertensive drugs 
in pregnancy; Faculty of Medicine, University of Tartu. 
2021 Annette Oder, BSc in Biology and Biodiversity Conservation, supervisor: 
Triin Kikas; Developing a protocol for detecting allelic variation in the 
dinucleotide rich regulatory region of the FLT1 gene; Faculty of Science 
and Technology, University of Tartu. 
 
Professional memberships 
2020–present European Society of Human Genetics 
2013–present Estonian Society of Human Genetics 
 
Publications 
1. Kikas, T, Laan, M, Kasak, L. (2021). Genetic variants shaping placental tran-
scriptome and their link to gestational and postnatal health. Placenta (in press) 
142 
2. Kikas, T, Inno, R, Ratnik, K, Rull, K, and Laan, M. (2020). C-allele of 
rs4769613 Near FLT1 Represents a High-Confidence Placental Risk Factor 
for Preeclampsia. Hypertens. 76, 884–891. 
3. Kikas, T, Rull, K, Beaumont, R.N, Freathy, R.M, and Laan, M. (2019). The 
Effect of Genetic Variation on the Placental Transcriptome in Humans. Front. 
Genet. 10, 550. 
4. Juhanson, P, Rull, K, Kikas, T, Laivuori, H, Vaas, P, Kajantie, E, Heinonen, S, 
and Laan, M. (2016). Stanniocalcin-1 Hormone in Nonpreeclamptic and 
Preeclamptic Pregnancy: Clinical, Life-Style, and Genetic Modulators. 
J. Clin. Endocrinol. Metab. 101, 4799–4807. 
5. Sõber, S., Reiman, M., Kikas, T., Rull, K., Inno, R., Vaas, P., Teesalu, P., 
Marti, J. M. L. J. M. L., Mattila, P. & Laan, M. (2015). Extensive shift in 
placental transcriptome profile in preeclampsia and placental origin of adverse 





Nimi:  Triin Kikas 
Sünniaeg: 7.11.1991 
Kodakondsus: eestlane 
E-post:  triin.kikas@ut.ee 
Telefon: +37253679767 
Haridus 
2010–2013 Loodusteaduste bakalaureusekraad (BSc) geenitehnoloogia 
õppekaval, Tartu Ülikool 
2013–2015 Loodusteaduste magistrikraad (MSc) biomeditsiini õppekaval, 
Tartu Ülikool 
2015–2021 Doktorant arstiteaduse õppekaval, Tartu Ülikool 
 
Erialane teenistuskäik 
2019–praegu Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirde-
meditsiini instituut, inimese geneetika nooremlektor 
2019–2020 Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirde-
meditsiini instituut, nooremteadur 
 
Juhendatud väitekirjad  
2019 Käbi-Riin Ojassoo, geenitehnoloogia bakalaureusekraad, juhendajad: 
Triin Kikas, Mario Reiman, Mihkel Vaher; Platsenta alternatiivne 
splaissing normaalses ja preeklamptilises raseduses; Loodus- ja tehno-
loogiateaduskond, Tartu Ülikool 
2019 Külliki Matt, farmaatsia magistrikraad, juhendajad: Kristiina Rull, Triin 
Kikas; FLT1 geeni polümorfismi seos preeklampsia ja teiste rasedus-
aegsete hüpertensiivsete haigustega ning antihüpertensiivsete ravimite 
vajadusega raseduse ajal; Meditsiiniteaduste valdkond, Tartu Ülikool 
2021 Annette Oder, bioloogia ja elustiku kaitse bakalaureusekraad, juhendaja: 
Triin Kikas; FLT1 geeni regulaatoralas paiknevate dinukleotiidi korduste 
rikka piirkonna alleelse varieeruvuse tuvastamise protokolli 
väljatöötamine; Loodus- ja tehnoloogiateaduskond, Tartu Ülikool 
 
Kuulumine erialaorganisatsioonidesse 
2013–praegu Eesti Inimesegeneetika Ühingu liige 
2020–praegu Euroopa Inimesegeneetika Ühingu liige 
 
Publikatsioonid 
1. Kikas, T, Laan, M, Kasak, L. (2021). Genetic variants shaping placental tran-
scriptome and their link to gestational and postnatal health. Placenta (avalda-
misel) 
144 
2. Kikas, T, Inno, R, Ratnik, K, Rull, K, and Laan, M. (2020). C-allele of 
rs4769613 Near FLT1 Represents a High-Confidence Placental Risk Factor 
for Preeclampsia. Hypertens. 76, 884–891. 
3. Kikas, T, Rull, K, Beaumont, R.N, Freathy, R.M, and Laan, M. (2019). The 
Effect of Genetic Variation on the Placental Transcriptome in Humans. Front. 
Genet. 10, 550. 
4. Juhanson, P, Rull, K, Kikas, T, Laivuori, H, Vaas, P, Kajantie, E, Heinonen, S, 
and Laan, M. (2016). Stanniocalcin-1 Hormone in Nonpreeclamptic and 
Preeclamptic Pregnancy: Clinical, Life-Style, and Genetic Modulators. J. 
Clin. Endocrinol. Metab. 101, 4799–4807. 
5. Sõber, S., Reiman, M., Kikas, T., Rull, K., Inno, R., Vaas, P., Teesalu, P., 
Marti, J. M. L. J. M. L., Mattila, P. & Laan, M. (2015). Extensive shift in 
placental transcriptome profile in preeclampsia and placental origin of adverse 
pregnancy outcomes. Scientific Reports, 5, 13336.  
https://doi.org/10.1038/srep13336 
145 
DISSERTATIONES MEDICINAE  
UNIVERSITATIS TARTUENSIS  
 1. Heidi-Ingrid Maaroos. The natural course of gastric ulcer in connection 
with chronic gastritis and Helicobacter pylori. Tartu, 1991. 
 2. Mihkel Zilmer. Na-pump in normal and tumorous brain tissues: Structu-
ral, functional and tumorigenesis aspects. Tartu, 1991. 
 3. Eero Vasar. Role of cholecystokinin receptors in the regulation of beha-
viour and in the action of haloperidol and diazepam. Tartu, 1992. 
 4. Tiina Talvik. Hypoxic-ischaemic brain damage in neonates (clinical, 
biochemical and brain computed tomographical investigation). Tartu, 1992. 
 5. Ants Peetsalu. Vagotomy in duodenal ulcer disease: A study of gastric 
acidity, serum pepsinogen I, gastric mucosal histology and Helicobacter 
pylori. Tartu, 1992. 
 6. Marika Mikelsaar. Evaluation of the gastrointestinal microbial ecosystem 
in health and disease. Tartu, 1992. 
 7. Hele Everaus. Immuno-hormonal interactions in chronic lymphocytic leu-
kaemia and multiple myeloma. Tartu, 1993. 
 8. Ruth Mikelsaar. Etiological factors of diseases in genetically consulted 
children and newborn screening: dissertation for the commencement of the 
degree of doctor of medical sciences. Tartu, 1993. 
 9. Agu Tamm. On metabolic action of intestinal microflora: clinical aspects. 
Tartu, 1993. 
 10. Katrin Gross. Multiple sclerosis in South-Estonia (epidemiological and 
computed tomographical investigations). Tartu, 1993. 
 11. Oivi Uibo. Childhood coeliac disease in Estonia: occurrence, screening, 
diagnosis and clinical characterization. Tartu, 1994. 
 12. Viiu Tuulik. The functional disorders of central nervous system of che-
mistry workers. Tartu, 1994. 
 13. Margus Viigimaa. Primary haemostasis, antiaggregative and anticoagulant 
treatment of acute myocardial infarction. Tartu, 1994. 
 14. Rein Kolk. Atrial versus ventricular pacing in patients with sick sinus 
syndrome. Tartu, 1994. 
 15. Toomas Podar. Incidence of childhood onset type 1 diabetes mellitus in 
Estonia. Tartu, 1994. 
 16. Kiira Subi. The laboratory surveillance of the acute respiratory viral 
infections in Estonia. Tartu, 1995. 
17. Irja Lutsar. Infections of the central nervous system in children (epidemi-
ologic, diagnostic and therapeutic aspects, long term outcome). Tartu, 1995. 
18. Aavo Lang. The role of dopamine, 5-hydroxytryptamine, sigma and 
NMDA receptors in the action of antipsychotic drugs. Tartu, 1995. 
19.  Andrus Arak. Factors influencing the survival of patients after radical 
surgery for gastric cancer. Tartu, 1996. 
146 
20.  Tõnis Karki. Quantitative composition of the human lactoflora and 
method for its examination. Tartu, 1996. 
21. Reet Mändar. Vaginal microflora during pregnancy and its transmission 
to newborn. Tartu, 1996.  
22. Triin Remmel. Primary biliary cirrhosis in Estonia: epidemiology, clinical 
characterization and prognostication of the course of the disease. Tartu, 
1996. 
23. Toomas Kivastik. Mechanisms of drug addiction: focus on positive rein-
forcing properties of morphine. Tartu, 1996.  
24.  Paavo Pokk. Stress due to sleep deprivation: focus on GABAA receptor-
chloride ionophore complex. Tartu, 1996. 
25. Kristina Allikmets. Renin system activity in essential hypertension. As-
sociations with atherothrombogenic cardiovascular risk factors and with 
the efficacy of calcium antagonist treatment. Tartu, 1996. 
26. Triin Parik. Oxidative stress in essential hypertension: Associations with 
metabolic disturbances and the effects of calcium antagonist treatment. 
Tartu, 1996. 
27.  Svetlana Päi. Factors promoting heterogeneity of the course of rheumatoid 
arthritis. Tartu, 1997.  
28. Maarike Sallo. Studies on habitual physical activity and aerobic fitness in 
4 to 10 years old children. Tartu, 1997. 
29. Paul Naaber. Clostridium difficile infection and intestinal microbial eco-
logy. Tartu, 1997. 
30. Rein Pähkla. Studies in pinoline pharmacology. Tartu, 1997. 
31. Andrus Juhan Voitk. Outpatient laparoscopic cholecystectomy. Tartu, 1997. 
32. Joel Starkopf. Oxidative stress and ischaemia-reperfusion of the heart. 
Tartu, 1997. 
33.  Janika Kõrv. Incidence, case-fatality and outcome of stroke. Tartu, 1998. 
34. Ülla Linnamägi. Changes in local cerebral blood flow and lipid peroxida-
tion following lead exposure in experiment. Tartu, 1998. 
35. Ave Minajeva. Sarcoplasmic reticulum function: comparison of atrial and 
ventricular myocardium. Tartu, 1998. 
36. Oleg Milenin. Reconstruction of cervical part of esophagus by revascular-
ised ileal autografts in dogs. A new complex multistage method. Tartu, 
1998. 
37. Sergei Pakriev. Prevalence of depression, harmful use of alcohol and 
alcohol dependence among rural population in Udmurtia. Tartu, 1998. 
38. Allen Kaasik. Thyroid hormone control over β-adrenergic signalling 
system in rat atria. Tartu, 1998. 
39. Vallo Matto. Pharmacological studies on anxiogenic and antiaggressive 
properties of antidepressants. Tartu, 1998. 
40. Maire Vasar. Allergic diseases and bronchial hyperreactivity in Estonian 
children in relation to environmental influences. Tartu, 1998. 
41. Kaja Julge. Humoral immune responses to allergens in early childhood. 
Tartu, 1998. 
147 
42. Heli Grünberg. The cardiovascular risk of Estonian schoolchildren. 
A cross-sectional study of 9-, 12- and 15-year-old children. Tartu, 1998. 
43. Epp Sepp. Formation of intestinal microbial ecosystem in children. Tartu, 
1998. 
44. Mai Ots. Characteristics of the progression of human and experimental 
glomerulopathies. Tartu, 1998. 
45. Tiina Ristimäe. Heart rate variability in patients with coronary artery 
disease. Tartu, 1998. 
46. Leho Kõiv. Reaction of the sympatho-adrenal and hypothalamo-pituitary-
adrenocortical system in the acute stage of head injury. Tartu, 1998. 
47. Bela Adojaan. Immune and genetic factors of childhood onset IDDM in 
Estonia. An epidemiological study. Tartu, 1999. 
48. Jakov Shlik. Psychophysiological effects of cholecystokinin in humans. 
Tartu, 1999. 
49. Kai Kisand. Autoantibodies against dehydrogenases of α-ketoacids. Tartu, 
1999. 
50. Toomas Marandi. Drug treatment of depression in Estonia. Tartu, 1999. 
51. Ants Kask. Behavioural studies on neuropeptide Y. Tartu, 1999. 
52. Ello-Rahel Karelson. Modulation of adenylate cyclase activity in the rat 
hippocampus by neuropeptide galanin and its chimeric analogs. Tartu, 1999. 
53. Tanel Laisaar. Treatment of pleural empyema — special reference to 
intrapleural therapy with streptokinase and surgical treatment modalities. 
Tartu, 1999. 
54. Eve Pihl. Cardiovascular risk factors in middle-aged former athletes. 
Tartu, 1999. 
55.  Katrin Õunap. Phenylketonuria in Estonia: incidence, newborn screening, 
diagnosis, clinical characterization and genotype/phenotype correlation. 
Tartu, 1999. 
56. Siiri Kõljalg. Acinetobacter – an important nosocomial pathogen. Tartu, 
1999. 
57. Helle Karro. Reproductive health and pregnancy outcome in Estonia: 
association with different factors. Tartu, 1999. 
58. Heili Varendi. Behavioral effects observed in human newborns during 
exposure to naturally occurring odors. Tartu, 1999.  
59. Anneli Beilmann. Epidemiology of epilepsy in children and adolescents in 
Estonia. Prevalence, incidence, and clinical characteristics. Tartu, 1999. 
60. Vallo Volke. Pharmacological and biochemical studies on nitric oxide in 
the regulation of behaviour. Tartu, 1999. 
61.  Pilvi Ilves. Hypoxic-ischaemic encephalopathy in asphyxiated term infants. 
A prospective clinical, biochemical, ultrasonographical study. Tartu, 1999. 
62. Anti Kalda. Oxygen-glucose deprivation-induced neuronal death and its 
pharmacological prevention in cerebellar granule cells. Tartu, 1999. 
63.  Eve-Irene Lepist. Oral peptide prodrugs – studies on stability and 
absorption. Tartu, 2000. 
148 
64. Jana Kivastik. Lung function in Estonian schoolchildren: relationship 
with anthropometric indices and respiratory symptomas, reference values 
for dynamic spirometry. Tartu, 2000. 
65. Karin Kull. Inflammatory bowel disease: an immunogenetic study. Tartu, 
2000. 
66. Kaire Innos. Epidemiological resources in Estonia: data sources, their 
quality and feasibility of cohort studies. Tartu, 2000. 
67. Tamara Vorobjova. Immune response to Helicobacter pylori and its 
association with dynamics of chronic gastritis and epithelial cell turnover 
in antrum and corpus. Tartu, 2001. 
68. Ruth Kalda. Structure and outcome of family practice quality in the 
changing health care system of Estonia. Tartu, 2001. 
69. Annika Krüüner. Mycobacterium tuberculosis – spread and drug 
resistance in Estonia. Tartu, 2001. 
70. Marlit Veldi. Obstructive Sleep Apnoea: Computerized Endopharyngeal 
Myotonometry of the Soft Palate and Lingual Musculature. Tartu, 2001. 
71. Anneli Uusküla. Epidemiology of sexually transmitted diseases in Estonia 
in 1990–2000. Tartu, 2001. 
72. Ade Kallas. Characterization of antibodies to coagulation factor VIII. 
Tartu, 2002. 
73. Heidi Annuk. Selection of medicinal plants and intestinal lactobacilli as 
antimicrobil components for functional foods. Tartu, 2002.  
74. Aet Lukmann. Early rehabilitation of patients with ischaemic heart 
disease after surgical revascularization of the myocardium:  assessment of 
health-related quality of life, cardiopulmonary reserve and oxidative stress. 
A clinical study. Tartu, 2002. 
75. Maigi Eisen. Pathogenesis of Contact Dermatitis: participation of Oxida-
tive Stress. A clinical – biochemical study. Tartu, 2002. 
76. Piret Hussar. Histology of the post-traumatic bone repair in rats. Elabora-
tion and use of a new standardized experimental model – bicortical perfora-
tion of tibia compared to internal fracture and resection osteotomy. Tartu, 
2002. 
77. Tõnu Rätsep. Aneurysmal subarachnoid haemorrhage: Noninvasive moni-
toring of cerebral haemodynamics. Tartu, 2002. 
78. Marju Herodes. Quality of life of people with epilepsy in Estonia. Tartu, 
2003. 
79. Katre Maasalu. Changes in bone quality due to age and genetic disorders 
and their clinical expressions in Estonia. Tartu, 2003. 
80. Toomas Sillakivi. Perforated peptic ulcer in Estonia: epidemiology, risk 
factors and relations with Helicobacter pylori. Tartu, 2003. 
81. Leena Puksa. Late responses in motor nerve conduction studies. F and A 
waves in normal subjects and patients with neuropathies. Tartu, 2003. 
82. Krista Lõivukene. Helicobacter pylori in gastric microbial ecology and  
its antimicrobial susceptibility pattern. Tartu, 2003. 
149 
83. Helgi Kolk. Dyspepsia and Helicobacter pylori infection: the diagnostic 
value of symptoms, treatment and follow-up of patients referred for upper 
gastrointestinal endoscopy by family physicians. Tartu, 2003. 
84. Helena Soomer. Validation of identification and age estimation methods 
in forensic odontology. Tartu, 2003. 
85. Kersti Oselin. Studies on the human MDR1, MRP1, and MRP2 ABC 
transporters: functional relevance of the genetic polymorphisms in the 
MDR1 and MRP1 gene. Tartu, 2003. 
86. Jaan Soplepmann. Peptic ulcer haemorrhage in Estonia: epidemiology, 
prognostic factors, treatment and outcome. Tartu, 2003. 
87. Margot Peetsalu. Long-term follow-up after vagotomy in duodenal ulcer 
disease: recurrent ulcer, changes in the function, morphology and Helico-
bacter pylori colonisation of the gastric mucosa. Tartu, 2003. 
88. Kersti Klaamas. Humoral immune response to Helicobacter pylori a study 
of host-dependent and microbial factors. Tartu, 2003. 
89. Pille Taba. Epidemiology of Parkinson’s disease in Tartu, Estonia. Pre-
valence, incidence, clinical characteristics, and pharmacoepidemiology. 
Tartu, 2003.  
90. Alar Veraksitš. Characterization of behavioural and biochemical pheno-
type of cholecystokinin-2 receptor deficient mice: changes in the function 
of the dopamine and endopioidergic system. Tartu, 2003. 
91. Ingrid Kalev. CC-chemokine receptor 5 (CCR5) gene polymorphism in 
Estonians and in patients with Type I and Type II diabetes mellitus. Tartu, 
2003. 
92. Lumme Kadaja. Molecular approach to the regulation of mitochondrial 
function in oxidative muscle cells. Tartu, 2003. 
93. Aive Liigant. Epidemiology of primary central nervous system tumours in 
Estonia from 1986 to 1996. Clinical characteristics, incidence, survival and 
prognostic factors. Tartu, 2004. 
94. Andres, Kulla. Molecular characteristics of mesenchymal stroma in 
human astrocytic gliomas. Tartu, 2004. 
95. Mari Järvelaid. Health damaging risk behaviours in adolescence. Tartu, 
2004. 
96. Ülle Pechter. Progression prevention strategies in chronic renal failure and 
hypertension. An experimental and clinical study. Tartu, 2004. 
97. Gunnar Tasa. Polymorphic glutathione S-transferases – biology and role 
in modifying genetic susceptibility to senile cataract and primary open 
angle glaucoma. Tartu, 2004. 
98. Tuuli Käämbre. Intracellular energetic unit: structural and functional 
aspects. Tartu, 2004. 
99.  Vitali Vassiljev. Influence of nitric oxide syntase inhibitors on the effects  
of ethanol after acute and chronic ethanol administration and withdrawal. 
Tartu, 2004. 
150 
100. Aune Rehema. Assessment of nonhaem ferrous iron and glutathione 
redox ratio as markers of pathogeneticity of oxidative stress in different 
clinical groups. Tartu, 2004. 
101.   Evelin Seppet. Interaction of mitochondria and ATPases in oxidative 
muscle cells in normal and pathological conditions. Tartu, 2004. 
102. Eduard Maron. Serotonin function in panic disorder: from clinical expe-
riments to brain imaging and genetics. Tartu, 2004.  
103. Marje Oona. Helicobacter pylori infection in children: epidemiological 
and therapeutic aspects. Tartu, 2004. 
104. Kersti Kokk. Regulation of active and passive molecular transport in the 
testis. Tartu, 2005.  
105. Vladimir Järv. Cross-sectional imaging for pretreatment evaluation and 
follow-up of pelvic malignant tumours. Tartu, 2005. 
106. Andre Õun. Epidemiology of adult epilepsy in Tartu, Estonia. Incidence, 
prevalence and medical treatment. Tartu, 2005. 
107. Piibe Muda. Homocysteine and hypertension: associations between 
homocysteine and essential hypertension in treated and untreated hyper-
tensive patients with and without coronary artery disease. Tartu, 2005. 
108. Külli Kingo. The interleukin-10 family cytokines gene polymorphisms in 
plaque psoriasis. Tartu, 2005.  
109. Mati Merila. Anatomy and clinical relevance of the glenohumeral joint  
capsule and ligaments. Tartu, 2005. 
110. Epp Songisepp. Evaluation of technological and functional properties of 
the new probiotic Lactobacillus fermentum ME-3. Tartu, 2005. 
111. Tiia Ainla. Acute myocardial infarction in Estonia: clinical characte-
ristics, management and outcome. Tartu, 2005. 
112. Andres Sell. Determining the minimum local anaesthetic requirements for 
hip replacement surgery under spinal anaesthesia – a study employing a 
spinal catheter. Tartu, 2005. 
113. Tiia Tamme. Epidemiology of odontogenic tumours in Estonia. Patho-
genesis and clinical behaviour of ameloblastoma. Tartu, 2005. 
114. Triine Annus. Allergy in Estonian schoolchildren: time trends and 
characteristics. Tartu, 2005. 
115. Tiia Voor. Microorganisms in infancy and development of allergy: com-
parison  of  Estonian  and Swedish  children. Tartu, 2005. 
116. Priit Kasenõmm. Indicators for tonsillectomy in adults with recurrent 
tonsillitis – clinical, microbiological and pathomorphological investi-
gations. Tartu, 2005. 
117. Eva Zusinaite. Hepatitis C virus: genotype identification and interactions 
between viral proteases. Tartu, 2005. 
118. Piret Kõll. Oral lactoflora in chronic periodontitis and periodontal health. 
Tartu, 2006. 
119. Tiina Stelmach. Epidemiology of cerebral palsy and unfavourable neuro-
developmental outcome in child population of Tartu city and county, 
Estonia Prevalence, clinical features and risk factors. Tartu, 2006. 
151 
120. Katrin Pudersell. Tropane alkaloid production and riboflavine excretion 
in the field and tissue cultures of henbane (Hyoscyamus niger L.). Tartu, 
2006.  
121. Külli Jaako. Studies on the role of neurogenesis in brain plasticity. Tartu, 
2006.  
122. Aare Märtson. Lower limb lengthening: experimental studies of bone 
regeneration and long-term clinical results. Tartu, 2006. 
123.  Heli Tähepõld. Patient consultation in family medicine. Tartu, 2006. 
124. Stanislav Liskmann. Peri-implant disease: pathogenesis, diagnosis and 
treatment in view of both inflammation and oxidative stress profiling. 
Tartu, 2006. 
125. Ruth Rudissaar. Neuropharmacology of atypical antipsychotics and an 
animal model of psychosis. Tartu, 2006. 
126. Helena Andreson. Diversity of Helicobacter pylori genotypes in 
Estonian patients with chronic inflammatory gastric diseases. Tartu, 2006. 
127. Katrin Pruus. Mechanism of action of antidepressants: aspects of sero-
toninergic system and its interaction with glutamate. Tartu, 2006. 
128. Priit Põder. Clinical and experimental investigation: relationship of 
ischaemia/reperfusion injury with oxidative stress in abdominal aortic 
aneurysm repair and in extracranial brain artery endarterectomy and possi-
bilities of protection against ischaemia using a glutathione analogue in a 
rat model of global brain ischaemia. Tartu, 2006.   
129. Marika Tammaru. Patient-reported outcome measurement in rheumatoid 
arthritis. Tartu, 2006. 
130.   Tiia Reimand. Down syndrome in Estonia. Tartu, 2006. 
131. Diva Eensoo. Risk-taking in traffic and Markers of Risk-Taking Beha-
viour in Schoolchildren and Car Drivers. Tartu, 2007. 
132. Riina Vibo. The third stroke registry in Tartu, Estonia from 2001 to 2003: 
incidence, case-fatality, risk factors and long-term outcome. Tartu, 2007.  
133. Chris Pruunsild. Juvenile idiopathic arthritis in children in Estonia. 
Tartu, 2007. 
134. Eve Õiglane-Šlik. Angelman and Prader-Willi syndromes in Estonia. 
Tartu, 2007. 
135. Kadri Haller. Antibodies to follicle stimulating hormone. Significance in 
female infertility. Tartu, 2007. 
136.  Pille Ööpik. Management of depression in family medicine. Tartu, 2007. 
137. Jaak Kals. Endothelial function and arterial stiffness in patients with 
atherosclerosis and in healthy subjects. Tartu, 2007. 
138.  Priit Kampus. Impact of inflammation, oxidative stress and age on 
arterial stiffness and carotid artery intima-media thickness. Tartu, 2007. 
139.  Margus Punab. Male fertility and its risk factors in Estonia. Tartu, 2007. 
140. Alar Toom. Heterotopic ossification after total hip arthroplasty: clinical 
and pathogenetic investigation. Tartu, 2007. 
152 
141. Lea Pehme. Epidemiology of tuberculosis in Estonia 1991–2003 with 
special regard to extrapulmonary tuberculosis and delay in diagnosis of 
pulmonary tuberculosis. Tartu, 2007. 
142.  Juri Karjagin. The pharmacokinetics of metronidazole and meropenem 
in septic shock. Tartu, 2007. 
143. Inga Talvik. Inflicted traumatic brain injury shaken baby syndrome in 
Estonia – epidemiology and outcome. Tartu, 2007. 
144.  Tarvo Rajasalu. Autoimmune diabetes: an immunological study of type 
1 diabetes in humans and in a model of experimental diabetes (in RIP-
B7.1 mice). Tartu, 2007. 
145. Inga Karu. Ischaemia-reperfusion injury of the heart during coronary 
surgery: a clinical study investigating the effect of hyperoxia. Tartu, 2007. 
146. Peeter Padrik. Renal cell carcinoma: Changes in natural history and 
treatment of metastatic disease. Tartu, 2007.  
147.  Neve Vendt. Iron deficiency and iron deficiency anaemia in infants aged 
9 to 12 months in Estonia. Tartu, 2008.  
148. Lenne-Triin Heidmets. The effects of neurotoxins on brain plasticity: 
focus on neural Cell Adhesion Molecule. Tartu, 2008. 
149.  Paul Korrovits. Asymptomatic inflammatory prostatitis: prevalence, etio-
logical factors, diagnostic tools. Tartu, 2008. 
150.   Annika Reintam. Gastrointestinal failure in intensive care patients. Tartu, 
2008. 
151.   Kristiina Roots. Cationic regulation of Na-pump in the normal, Alzhei-
mer’s and CCK2 receptor-deficient brain. Tartu, 2008. 
152. Helen Puusepp. The genetic causes of mental retardation in Estonia: 
fragile X syndrome and creatine transporter defect. Tartu, 2009. 
153. Kristiina Rull. Human chorionic gonadotropin beta genes and recurrent 
miscarriage: expression and variation study. Tartu, 2009. 
154.  Margus Eimre. Organization of energy transfer and feedback regulation 
in oxidative muscle cells. Tartu, 2009. 
155. Maire Link. Transcription factors FoxP3 and AIRE: autoantibody 
associations. Tartu, 2009. 
156.  Kai Haldre. Sexual health and behaviour of young women in Estonia. 
Tartu, 2009. 
157. Kaur Liivak. Classical form of congenital adrenal hyperplasia due to  
21-hydroxylase deficiency in Estonia: incidence, genotype and phenotype 
with special attention to short-term growth and 24-hour blood pressure. 
Tartu, 2009. 
158. Kersti Ehrlich. Antioxidative glutathione analogues (UPF peptides) – 
molecular design, structure-activity relationships and testing the protec-
tive properties. Tartu, 2009. 
159. Anneli Rätsep. Type 2 diabetes care in family medicine. Tartu, 2009. 
160. Silver Türk. Etiopathogenetic aspects of chronic prostatitis: role of 
mycoplasmas, coryneform bacteria and oxidative stress. Tartu, 2009. 
153 
161. Kaire Heilman. Risk markers for cardiovascular disease and low bone 
mineral density in children with type 1 diabetes. Tartu, 2009. 
162.  Kristi Rüütel. HIV-epidemic in Estonia: injecting drug use and quality of 
life of people living with HIV. Tartu, 2009. 
163. Triin Eller. Immune markers in major depression and in antidepressive 
treatment. Tartu, 2009. 
164.  Siim Suutre. The role of TGF-β isoforms and osteoprogenitor cells in the 
pathogenesis of heterotopic ossification. An experimental and clinical 
study of hip arthroplasty. Tartu, 2010. 
165.  Kai Kliiman. Highly drug-resistant tuberculosis in Estonia: Risk factors 
and predictors of poor treatment outcome. Tartu, 2010.  
166.  Inga Villa. Cardiovascular health-related nutrition, physical activity and 
fitness in Estonia. Tartu, 2010. 
167. Tõnis Org. Molecular function of the first PHD finger domain of Auto-
immune Regulator protein. Tartu, 2010.  
168. Tuuli Metsvaht. Optimal antibacterial therapy of neonates at risk of early 
onset sepsis. Tartu, 2010. 
169.  Jaanus Kahu. Kidney transplantation: Studies on donor risk factors and 
mycophenolate mofetil. Tartu, 2010.  
170.  Koit Reimand. Autoimmunity in reproductive failure: A study on as-
sociated autoantibodies and autoantigens. Tartu, 2010. 
171. Mart Kull. Impact of vitamin D and hypolactasia on bone mineral 
density: a population based study in Estonia. Tartu, 2010. 
172. Rael Laugesaar. Stroke in children – epidemiology and risk factors. 
Tartu, 2010.  
173.  Mark Braschinsky. Epidemiology and quality of life issues of hereditary 
spastic paraplegia in Estonia and implemention of genetic analysis in 
everyday neurologic practice. Tartu, 2010. 
174. Kadri Suija. Major depression in family medicine: associated factors, 
recurrence and possible intervention. Tartu, 2010. 
175. Jarno Habicht. Health care utilisation in Estonia: socioeconomic determi-
nants and financial burden of out-of-pocket payments. Tartu, 2010. 
176. Kristi Abram. The prevalence and risk factors of rosacea. Subjective 
disease perception of rosacea patients. Tartu, 2010. 
177. Malle Kuum. Mitochondrial and endoplasmic reticulum cation fluxes: 
Novel roles in cellular physiology. Tartu, 2010. 
178. Rita Teek. The genetic causes of early onset hearing loss in Estonian 
children. Tartu, 2010. 
179. Daisy Volmer. The development of community pharmacy services in 
Estonia – public and professional perceptions 1993–2006. Tartu, 2010. 
180. Jelena Lissitsina. Cytogenetic causes in male infertility. Tartu, 2011. 
181.  Delia Lepik. Comparison of gunshot injuries caused from Tokarev, 
Makarov and Glock 19 pistols at different firing distances. Tartu, 2011. 
182.  Ene-Renate Pähkla. Factors related to the efficiency of treatment of 
advanced periodontitis. Tartu, 2011.  
154 
183. Maarja Krass. L-Arginine pathways and antidepressant action. Tartu, 
2011.  
184.  Taavi Lai. Population health measures to support evidence-based  
health policy in Estonia. Tartu, 2011.  
185. Tiit Salum. Similarity and difference of temperature-dependence of the 
brain sodium pump in normal, different neuropathological, and aberrant 
conditions and its possible reasons. Tartu, 2011.  
186.  Tõnu Vooder. Molecular differences and similarities between histo-
logical subtypes of non-small cell lung cancer. Tartu, 2011.  
187.  Jelena Štšepetova. The characterisation of intestinal lactic acid bacteria 
using bacteriological, biochemical and molecular approaches. Tartu, 2011.  
188. Radko Avi. Natural polymorphisms and transmitted drug resistance in 
Estonian HIV-1 CRF06_cpx and its recombinant viruses. Tartu, 2011, 116 p. 
189.  Edward Laane. Multiparameter flow cytometry in haematological malig-
nancies. Tartu, 2011, 152 p. 
190.  Triin Jagomägi. A study of the genetic etiology of nonsyndromic cleft lip 
and palate. Tartu, 2011, 158 p. 
191.  Ivo Laidmäe. Fibrin glue of fish (Salmo salar) origin: immunological 
study and development of new pharmaceutical preparation. Tartu, 2012, 
150 p. 
192.  Ülle Parm. Early mucosal colonisation and its role in prediction of inva-
sive infection in neonates at risk of early onset sepsis. Tartu, 2012, 168 p. 
193.  Kaupo Teesalu. Autoantibodies against desmin and transglutaminase 2 in 
celiac disease: diagnostic and functional significance. Tartu, 2012, 142 p. 
194. Maksim Zagura. Biochemical, functional and structural profiling of 
arterial damage in atherosclerosis. Tartu, 2012, 162 p. 
195. Vivian Kont. Autoimmune regulator: characterization of thymic gene 
regulation and promoter methylation. Tartu, 2012, 134 p. 
196. Pirje Hütt. Functional properties, persistence, safety and efficacy of 
potential probiotic lactobacilli. Tartu, 2012, 246 p. 
197.  Innar Tõru. Serotonergic modulation of CCK-4- induced panic. Tartu, 
2012, 132 p. 
198.  Sigrid Vorobjov. Drug use, related risk behaviour and harm reduction 
interventions utilization among injecting drug users in Estonia: impli-
cations for drug policy. Tartu, 2012, 120 p. 
199.  Martin Serg. Therapeutic aspects of central haemodynamics, arterial 
stiffness and oxidative stress in hypertension. Tartu, 2012, 156 p.  
200. Jaanika Kumm. Molecular markers of articular tissues in early knee 
osteoarthritis: a population-based longitudinal study in middle-aged sub-
jects. Tartu, 2012, 159 p. 
201. Kertu Rünkorg. Functional changes of dopamine, endopioid and endo-
cannabinoid systems in CCK2 receptor deficient mice. Tartu, 2012, 125 p. 
202. Mai Blöndal. Changes in the baseline characteristics, management and 
outcomes of acute myocardial infarction in Estonia. Tartu, 2012, 127 p.        
155 
203. Jana Lass. Epidemiological and clinical aspects of medicines use in 
children in Estonia. Tartu, 2012, 170 p. 
204. Kai Truusalu. Probiotic lactobacilli in experimental persistent Salmo-
nella infection. Tartu, 2013, 139 p.  
205. Oksana Jagur.  Temporomandibular joint diagnostic imaging in relation 
to pain and bone characteristics. Long-term results of arthroscopic treat-
ment. Tartu, 2013, 126 p. 
206. Katrin Sikk. Manganese-ephedrone intoxication – pathogenesis of neuro-
logical damage and clinical symptomatology. Tartu, 2013, 125 p. 
207. Kai Blöndal. Tuberculosis in Estonia with special emphasis on drug-
resistant tuberculosis: Notification rate, disease recurrence and mortality. 
Tartu, 2013, 151 p. 
208. Marju Puurand. Oxidative phosphorylation in different diseases of 
gastric mucosa. Tartu, 2013, 123 p.  
209. Aili Tagoma. Immune activation in female infertility: Significance of 
autoantibodies and inflammatory mediators. Tartu, 2013, 135 p. 
210.  Liis Sabre. Epidemiology of traumatic spinal cord injury in Estonia. 
Brain activation in the acute phase of traumatic spinal cord injury. Tartu, 
2013, 135 p. 
211. Merit Lamp. Genetic susceptibility factors in endometriosis. Tartu, 2013, 
125 p. 
212.  Erik Salum. Beneficial effects of vitamin D and angiotensin II receptor 
blocker on arterial damage. Tartu, 2013, 167 p.   
213.  Maire Karelson. Vitiligo: clinical aspects, quality of life and the role of 
melanocortin system in pathogenesis. Tartu, 2013, 153 p.  
214. Kuldar Kaljurand. Prevalence of exfoliation syndrome in Estonia and its 
clinical significance. Tartu, 2013, 113 p.  
215.  Raido Paasma. Clinical study of methanol poisoning: handling large out-
breaks, treatment with antidotes, and long-term outcomes. Tartu, 2013,  
96 p. 
216.  Anne Kleinberg. Major depression in Estonia: prevalence, associated 
factors, and use of health services. Tartu, 2013, 129 p. 
217.  Triin Eglit. Obesity, impaired glucose regulation, metabolic syndrome 
and their associations with high-molecular-weight adiponectin levels. 
Tartu, 2014, 115 p. 
218.  Kristo Ausmees. Reproductive function in middle-aged males: Asso-
ciations with prostate, lifestyle and couple infertility status. Tartu, 2014, 
125 p.  
219.  Kristi Huik. The influence of host genetic factors on the susceptibility to 
HIV and HCV infections among intravenous drug users. Tartu, 2014, 
144 p.  
220. Liina Tserel. Epigenetic profiles of monocytes, monocyte-derived macro-
phages and dendritic cells. Tartu, 2014, 143 p. 
221. Irina Kerna. The contribution of ADAM12 and CILP genes to the 
development of knee osteoarthritis. Tartu, 2014, 152 p. 
156 
222. Ingrid Liiv. Autoimmune regulator protein interaction with DNA-depen-
dent protein kinase and its role in apoptosis. Tartu, 2014, 143 p. 
223.  Liivi Maddison. Tissue perfusion and metabolism during intra-abdominal 
hypertension. Tartu, 2014, 103 p. 
224.  Krista Ress. Childhood coeliac disease in Estonia, prevalence in atopic 
dermatitis and immunological characterisation of coexistence. Tartu, 
2014, 124 p. 
225.  Kai Muru. Prenatal screening strategies, long-term outcome of children 
with marked changes in maternal screening tests and the most common 
syndromic heart anomalies in Estonia. Tartu, 2014, 189 p. 
226. Kaja Rahu. Morbidity and mortality among Baltic Chernobyl cleanup 
workers: a register-based cohort study. Tartu, 2014, 155 p.  
227.  Klari Noormets. The development of diabetes mellitus, fertility and 
energy metabolism disturbances in a Wfs1-deficient mouse model of 
Wolfram syndrome. Tartu, 2014, 132 p. 
228. Liis Toome. Very low gestational age infants in Estonia. Tartu, 2014,  
183 p. 
229.  Ceith Nikkolo. Impact of different mesh parameters on chronic pain and 
foreign body feeling after open inguinal hernia repair. Tartu, 2014, 132 p. 
230.  Vadim Brjalin. Chronic hepatitis C: predictors of treatment response in 
Estonian patients. Tartu, 2014, 122 p. 
231.  Vahur Metsna. Anterior knee pain in patients following total knee arthro-
plasty: the prevalence, correlation with patellar cartilage impairment and 
aspects of patellofemoral congruence. Tartu, 2014, 130 p. 
232.  Marju Kase. Glioblastoma multiforme: possibilities to improve treatment 
efficacy. Tartu, 2015, 137 p.  
233. Riina Runnel. Oral health among elementary school children and the 
effects of polyol candies on the prevention of dental caries. Tartu, 2015, 
112 p. 
234. Made Laanpere. Factors influencing women’s sexual health and re-
productive choices in Estonia. Tartu, 2015, 176 p. 
235.  Andres Lust. Water mediated solid state transformations of a polymorphic 
drug – effect on pharmaceutical product performance. Tartu, 2015, 134 p.  
236. Anna Klugman. Functionality related characterization of pretreated wood 
lignin, cellulose and polyvinylpyrrolidone for pharmaceutical applications. 
Tartu, 2015, 156 p. 
237. Triin Laisk-Podar. Genetic variation as a modulator of susceptibility to 
female infertility and a source for potential biomarkers. Tartu, 2015, 155 p. 
238. Mailis Tõnisson. Clinical picture and biochemical changes in blood in 
children with acute alcohol intoxication. Tartu, 2015, 100 p. 
239. Kadri Tamme. High volume haemodiafiltration in treatment of severe 
sepsis – impact on pharmacokinetics of antibiotics and inflammatory 




240. Kai Part. Sexual health of young people in Estonia in a social context: the 
role of school-based sexuality education and youth-friendly counseling 
services. Tartu, 2015, 203 p. 
241. Urve Paaver. New perspectives for the amorphization and physical 
stabilization of poorly water-soluble drugs and understanding their dis-
solution behavior. Tartu, 2015, 139 p. 
242. Aleksandr Peet. Intrauterine and postnatal growth in children with HLA-
conferred susceptibility to type 1 diabetes. Tartu. 2015, 146 p. 
243. Piret Mitt. Healthcare-associated infections in Estonia – epidemiology 
and surveillance of bloodstream and surgical site infections. Tartu, 2015, 
145 p. 
244.  Merli Saare. Molecular Profiling of Endometriotic Lesions and Endo-
metria of Endometriosis Patients. Tartu, 2016, 129 p. 
245.  Kaja-Triin Laisaar. People living with HIV in Estonia: Engagement in 
medical care and methods of increasing adherence to antiretroviral therapy 
and safe sexual behavior. Tartu, 2016, 132 p. 
246. Eero Merilind. Primary health care performance: impact of payment and 
practice-based characteristics. Tartu, 2016, 120 p. 
247. Jaanika Kärner. Cytokine-specific autoantibodies in AIRE deficiency. 
Tartu, 2016, 182 p. 
248. Kaido Paapstel. Metabolomic profile of arterial stiffness and early bio-
markers of renal damage in atherosclerosis. Tartu, 2016, 173 p. 
249.  Liidia Kiisk. Long-term nutritional study: anthropometrical and clinico-
laboratory assessments in renal replacement therapy patients after inten-
sive nutritional counselling. Tartu, 2016, 207 p. 
250. Georgi Nellis. The use of excipients in medicines administered to neo-
nates in Europe. Tartu, 2017, 159 p. 
251.  Aleksei Rakitin. Metabolic effects of acute and chronic treatment with 
valproic acid in people with epilepsy. Tartu, 2017, 125 p. 
252. Eveli Kallas. The influence of immunological markers to susceptibility to 
HIV, HBV, and HCV infections among persons who inject drugs. Tartu, 
2017, 138 p. 
253. Tiina Freimann. Musculoskeletal pain among nurses: prevalence, risk 
factors, and intervention. Tartu, 2017, 125 p. 
254.  Evelyn Aaviksoo. Sickness absence in Estonia: determinants and 
influence of the sick-pay cut reform. Tartu, 2017, 121 p. 
255. Kalev Nõupuu. Autosomal-recessive Stargardt disease: phenotypic 
heterogeneity and genotype-phenotype associations. Tartu, 2017, 131 p. 
256. Ho Duy Binh. Osteogenesis imperfecta in Vietnam. Tartu, 2017, 125 p. 
257.  Uku Haljasorg. Transcriptional mechanisms in thymic central tolerance. 
Tartu, 2017, 147 p.  
258.  Živile Riispere. IgA Nephropathy study according to the Oxford Classi-
fication: IgA Nephropathy clinical-morphological correlations, disease 
progression and the effect of renoprotective therapy. Tartu, 2017, 129 p. 
158 
259. Hiie Soeorg. Coagulase-negative staphylococci in gut of preterm neonates 
and in breast milk of their mothers. Tartu, 2017, 216 p. 
260. Anne-Mari Anton Willmore. Silver nanoparticles for cancer research. 
Tartu, 2017, 132 p. 
261.  Ott Laius. Utilization of osteoporosis medicines, medication adherence 
and the trend in osteoporosis related hip fractures in Estonia. Tartu, 2017,  
134 p.  
262. Alar Aab. Insights into molecular mechanisms of asthma and atopic 
dermatitis. Tartu, 2017, 164 p. 
263. Sander Pajusalu. Genome-wide diagnostics of Mendelian disorders:  
from chromosomal microarrays to next-generation sequencing. Tartu, 
2017, 146 p. 
264.  Mikk Jürisson. Health and economic impact of hip fracture in Estonia. 
Tartu, 2017, 164 p. 
265. Kaspar Tootsi. Cardiovascular and metabolomic profiling of osteo-
arthritis. Tartu, 2017, 150 p. 
266. Mario Saare. The influence of AIRE on gene expression – studies of 
transcriptional regulatory mechanisms in cell culture systems. Tartu, 2017, 
172 p. 
267. Piia Jõgi. Epidemiological and clinical characteristics of pertussis in 
Estonia. Tartu, 2018, 168 p. 
268. Elle Põldoja. Structure and blood supply of the superior part of the 
shoulder joint capsule. Tartu, 2018, 116 p. 
269. Minh Son Nguyen. Oral health status and prevalence of temporo-
mandibular disorders in 65–74-year-olds in Vietnam. Tartu, 2018, 182 p. 
270.  Kristian Semjonov. Development of pharmaceutical quench-cooled 
molten and melt-electrospun solid dispersions for poorly water-soluble 
indomethacin. Tartu, 2018, 125 p. 
271.  Janne Tiigimäe-Saar. Botulinum neurotoxin type A treatment for 
sialorrhea in central nervous system diseases. Tartu, 2018, 109 p. 
272. Veiko Vengerfeldt. Apical periodontitis: prevalence and etiopathogenetic 
aspects. Tartu, 2018,  150 p.  
273. Rudolf Bichele. TNF superfamily and AIRE at the crossroads of thymic 
differentiation and host protection against Candida albicans infection. 
Tartu, 2018, 153 p.  
274. Olga Tšuiko. Unravelling Chromosomal Instability in Mammalian Pre-
implantation Embryos Using Single-Cell Genomics. Tartu, 2018, 169 p. 
275.  Kärt Kriisa. Profile of acylcarnitines, inflammation and oxidative stress 
in first-episode psychosis before and after antipsychotic treatment. Tartu, 
2018, 145 p. 
276.  Xuan Dung Ho. Characterization of the genomic profile of osteosarcoma. 
Tartu, 2018, 144 p. 
277.  Karit Reinson. New Diagnostic Methods for Early Detection of Inborn 
Errors of Metabolism in Estonia. Tartu, 2018, 201 p. 
159 
278.  Mari-Anne Vals. Congenital N-glycosylation Disorders in Estonia. Tartu, 
2019, 148 p. 
279. Liis Kadastik-Eerme. Parkinson’s disease in Estonia: epidemiology, 
quality of life, clinical characteristics and pharmacotherapy. Tartu, 2019,  
202 p. 
280. Hedi Hunt. Precision targeting of intraperitoneal tumors with peptide-
guided nanocarriers. Tartu, 2019, 179 p. 
281.  Rando Porosk. The role of oxidative stress in Wolfram syndrome 1 and 
hypothermia. Tartu, 2019, 123 p. 
282. Ene-Ly Jõgeda. The influence of coinfections and host genetic factor on 
the susceptibility to HIV infection among people who inject drugs. Tartu, 
2019, 126 p. 
283. Kristel Ehala-Aleksejev. The associations between body composition, 
obesity and obesity-related health and lifestyle conditions with male 
reproductive function. Tartu, 2019, 138 p. 
284.  Aigar Ottas. The metabolomic profiling of psoriasis, atopic dermatitis 
and atherosclerosis. Tartu, 2019, 136 p. 
285.  Elmira Gurbanova. Specific characteristics of tuberculosis in low de-
fault, but high multidrug–resistance prison setting. Tartu, 2019, 129 p. 
286.  Van Thai Nguyeni. The first study of the treatment outcomes of patients 
with cleft lip and palate in Central Vietnam. Tartu, 2019, 144 p. 
287.  Maria Yakoreva. Imprinting Disorders in Estonia. Tartu, 2019, 187 p. 
288.  Kadri Rekker. The putative role of microRNAs in endometriosis patho-
genesis and potential in diagnostics. Tartu, 2019, 140 p. 
289. Ülle Võhma. Association between personality traits, clinical characteris-
tics and pharmacological treatment response in panic disorder. Tartu, 
2019, 121 p. 
290. Aet Saar. Acute myocardial infarction in Estonia 2001–2014: towards 
risk-based prevention and management. Tartu, 2019, 124 p. 
291.  Toomas Toomsoo. Transcranial brain sonography in the Estonian cohort 
of Parkinson’s disease. Tartu, 2019, 114 p. 
292.  Lidiia Zhytnik. Inter- and intrafamilial diversity based on genotype and 
phenotype correlations of Osteogenesis Imperfecta. Tartu, 2019, 224 p. 
293.  Pilleriin Soodla. Newly HIV-infected people in Estonia: estimation of 
incidence and transmitted drug resistance. Tartu, 2019, 194 p. 
294. Kristiina Ojamaa. Epidemiology of gynecological cancer in Estonia. 
Tartu, 2020, 133 p. 
295. Marianne Saard. Modern Cognitive and Social Intervention Techniques 
in Paediatric Neurorehabilitation for Children with Acquired Brain Injury. 
Tartu, 2020, 168 p. 
296. Julia Maslovskaja. The importance of DNA binding and DNA breaks for 
AIRE-mediated transcriptional activation. Tartu, 2020, 162 p. 
297. Natalia Lobanovskaya. The role of PSA-NCAM in the survival of retinal 
ganglion cells. Tartu, 2020, 105 p. 
298.  Madis Rahu. Structure and blood supply of the postero-superior part of 
the shoulder joint capsule with implementation of surgical treatment after 
anterior traumatic dislocation. Tartu, 2020, 104 p. 
299. Helen Zirnask. Luteinizing hormone (LH) receptor expression in the 
penis and its possible role in pathogenesis of erectile disturbances. Tartu, 
2020, 87 p. 
300.  Kadri Toome. Homing peptides for targeting of brain diseases. Tartu, 
2020, 152 p. 
301.  Maarja Hallik. Pharmacokinetics and pharmacodynamics of inotropic 
drugs in neonates. Tartu, 2020,  172 p. 
302.  Raili Müller. Cardiometabolic risk profile and body composition in early 
rheumatoid arthritis. Tartu, 2020, 133 p. 
303. Sergo Kasvandik. The role of proteomic changes in endometrial cells – 
from the perspective of fertility and endometriosis. Tartu, 2020, 191 p. 
304. Epp Kaleviste. Genetic variants revealing the role of STAT1/STAT3 
signaling cytokines in immune protection and pathology. Tartu, 2020, 
189 p. 
305.  Sten Saar. Epidemiology of severe injuries in Estonia. Tartu, 2020, 104 p. 
306.  Kati Braschinsky. Epidemiology of primary headaches in Estonia and 
applicability of web-based solutions in headache epidemiology research. 
Tartu, 2020, 129 p. 
307. Helen Vaher. MicroRNAs in the regulation of keratinocyte responses in 
psoriasis vulgaris and atopic dermatitis. Tartu, 2020, 242 p. 
308. Liisi Raam. Molecular Alterations in the Pathogenesis of Two Chronic 
Dermatoses – Vitiligo and Psoriasis. Tartu, 2020, 164 p. 
309.  Artur Vetkas. Long-term quality of life, emotional health, and associated 
factors in patients after aneurysmal subarachnoid haemorrhage. Tartu, 
2020, 127 p. 
310. Teele Kasepalu. Effects of remote ischaemic preconditioning on organ 
damage and acylcarnitines’ metabolism in vascular surgery. Tartu, 2020, 
130 p. 
311.  Prakash Lingasamy. Development of multitargeted tumor penetrating 
peptides. Tartu, 2020, 246 p. 
312.  Lille Kurvits. Parkinson’s disease as a multisystem disorder: whole trans-
criptome study in Parkinson’s disease patients’ skin and blood. Tartu, 
2021, 142 p. 
313.  Mariliis Põld. Smoking, attitudes towards smoking behaviour, and nico-
tine dependence among physicians in Estonia: cross-sectional surveys 
1982–2014. Tartu, 2021, 172 p. 
